Heterocyclic compounds as kinase inhibitors and their use
By providing new CHK-1 inhibitor compounds and their salts, the problem of limited effectiveness of existing CHK-1 inhibitors in the treatment of p53 pathway-deficient cancers is solved, improving pharmacokinetic and pharmacodynamic performance, and enhancing The killing ability to tumor cells reduces the toxicity to normal cells.
Patent Information
- Application Number
- CN202080069027.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-01
- Filing Date
- 2020-07-31
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-07-31
AI Technical Summary
The existing CHK-1 inhibitors have limited effectiveness in the treatment of p53 pathway-deficient cancers, and their pharmacokinetic and pharmacodynamic performance are insufficient, making them difficult to use as effective agents.
A novel compound formula (IA) and its salts are provided for inhibiting CHK-1 kinase, prepared by synthetic methods, and used in combination with other therapeutic agents to improve therapeutic effects.
Improve the pharmacokinetic and pharmacodynamic properties of CHK-1 inhibitors, enhance the therapeutic effect on p53 pathway-deficient cancer, increase the lethality rate of tumor cells, reduce the toxicity to normal cells, and improve chemotherapy drugs therapeutic activity.
Smart Images

Figure CN114728949B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to Indian Provisional Patent Application No. 201911004152 filed on August 1, 2019, the disclosure of which is incorporated herein by reference in its entirety. Technical Field
[0003] In general, the present invention relates to compounds having checkpoint kinase-1 (CHK-1) inhibitory activity. The present invention also discloses methods of using such compounds to treat conditions associated with excessive activity of the CHK-1 enzyme, pharmaceutical compositions, methods of treatment using the pharmaceutical compositions, and kits. Also disclosed are methods of synthesizing the compounds. Background Art
[0004] A variety of cancer chemotherapeutics work through DNA damage pathways to induce DNA damage, thereby inhibiting tumor growth. However, these chemotherapeutics cause cell cycle arrest by inducing checkpoints at the S phase or G2 / M boundary. G2 phase arrest allows cells to have time to repair damaged DNA before entering mitosis. Checkpoint kinase-1 (CHK-1) and unrelated serine / threonine kinases-checkpoint kinase-2 (CHK-2) play a central role in arresting the cell cycle at the G2-M boundary (O'Connell et al., EMBO J (1997), Vol. 16, pp. 545-554). CHK-1 and / or CHK-2 induce the checkpoint by phosphorylating serine 216 of CDC25 phosphatase, thereby inhibiting the removal of two inactivated phosphates on cyclin-dependent kinases (Zheng et al., Nature (1998), Vol. 395, pp. 507-510). Another overlapping pathway mediated by p53 also responds to DNA damage and causes cycle arrest. However, p53 is inactivated by mutation in many cancers, resulting in partial loss of its ability to initiate DNA repair responses. If CHK-1 activity is also inhibited in p53 negative cancers, all abilities to stagnate and repair DNA in response to DNA damage will be eliminated, resulting in mitotic catastrophe and enhancing the effect of DNA damaging agents (Konarias et al., Oncogene (2001), Vol. 20, pp. 7453-7463, Bunch and Eastman Clin. Can. Res. (1996) Vol. 2, pp. 791-797, Tenzer and Pruschy Curr. Med Chem (2003) Vol. 3, pp. 35-46).
[0005] Thus, CHK-1 inhibition represents a novel therapeutic strategy to increase the lethality of DNA-damaging chemotherapeutics in p53 pathway-deficient cancers. Abrogation of the remaining intact checkpoint should result in increased tumor cell death. CHK-1 inhibitors have demonstrated potentiation of a range of cytotoxic chemotherapeutics, including gemcitabine, irinotecan, cytarabine, and cisplatin, in vitro and in a range of preclinical models of human cancer. This “synthetic lethality” approach should increase the therapeutic activity of chemotherapeutics without increasing systemic toxicity, as normal cells should still be protected by their functional p53 pathways. Thus, CHK-1 inhibitors have the potential to be used in combination with a variety of cytotoxic chemotherapeutic agents to treat a variety of human cancers.
[0006] Various attempts have been made to develop CHK-1 kinase inhibitors. For example, US10000481B2 (Vernalis) discloses 1H-pyrrolo[2,3-B]pyridine derivative compounds as CHK-1 kinase inhibitors. US10010547B2 (Cascadian Therapeutics) discloses pyrazolaminopyrazine derivatives as kinase inhibitors. WO / 2018 / 086546A1 (Zhejiang University) discloses 2-polysubstituted aromatic ring-pyrimidine derivatives as CHK-1 inhibitors. Very few small molecule CHK-1 inhibitors (Prexasertib / LY2606368, LY2603618, and SRA737) are currently in combination with gemcitabine, pemetrexed, fludarabine, cytarabine, and cisplatin for phase I / II clinical evaluation.
[0007] Therefore, there remains a need to develop novel CHK-1 inhibitors having pharmacokinetic and pharmacodynamic properties that make them suitable for use as pharmaceutical agents. It is an object of the present invention to provide such pharmaceutical and therapeutic agents. Summary of the invention
[0008] In one aspect, the present invention provides a compound of formula (IA) or a salt thereof:
[0009]
[0010] Among them, A, D, L, Y and R 1 As detailed in this article.
[0011] In one aspect, the compound of formula (IA) or a salt thereof is a compound of formula (I) or a salt thereof as described in detail herein.
[0012] In one aspect, the compound of formula (IA) or a salt thereof is a compound of formula (II) or a salt thereof as described in detail herein.
[0013] In one aspect, the compound of formula (IA) or a salt thereof is a compound of formula (III) or a salt thereof as described in detail herein.
[0014] In one aspect, the compound of formula (IA) or a salt thereof is a compound of formula (IV) or a salt thereof as described in detail herein.
[0015] In some aspects, the compound of formula (II) or a salt thereof is any one of the compounds of formula (IIa-1) to (IIa-10) or a salt thereof as described in detail herein.
[0016] In some aspects, the compound of formula (II) or a salt thereof is any one of the compounds of formula (IIb-1) to (IIb-20) or a salt thereof as described in detail herein.
[0017] In some aspects, the compound of formula (III) or a salt thereof is any one of the compounds of formula (IIIa-1) to (IIIa-10) or a salt thereof as described in detail herein.
[0018] In some aspects, the compound of formula (III) or a salt thereof is any one of the compounds of formula (IIIb-1) to (IIIb-20) or a salt thereof as described in detail herein.
[0019] In some aspects, the compound of formula (IV) or a salt thereof is any one of the compounds of formula (IVa-1) to (IVa-15) or a salt thereof as described in detail herein.
[0020] In some additional aspects, the present invention provides a method of treating a disease or condition associated with the CHK kinase, more specifically CHK-1 kinase, in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a compound of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a salt thereof.
[0021] In some additional aspects, the present invention provides a method of inhibiting CHK-1 kinase in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a compound of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a salt thereof.
[0022] In some additional aspects, the present invention provides a method of treating cancer in an individual in need thereof, wherein the method comprises administering to the individual an effective amount of a compound of the present invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a salt thereof.
[0023] In some additional aspects, the present invention provides a method of treating a disease or condition associated with the CHK kinase, or more specifically CHK-1 kinase, in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a compound of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a salt thereof in combination with another therapeutic agent.
[0024] In some additional aspects, the present invention provides a pharmaceutical composition comprising a compound of the present invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a salt thereof and at least one pharmaceutically acceptable carrier.
[0025] In some additional aspects, the present invention provides a method of treating a disease or condition associated with the CHK kinase, or more specifically CHK-1 kinase, in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a pharmaceutical composition comprising a compound of the present invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a salt thereof.
[0026] In some additional aspects, the present invention provides a method of treating a disease or condition associated with the CHK kinase, or more specifically CHK-1 kinase, in an individual in need thereof, wherein the method comprises administering to the individual an effective amount of a composition comprising a compound of the present invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a salt thereof in combination with another therapeutic agent.
[0027] In some additional aspects, the present invention provides methods for preparing the compounds disclosed herein and their intermediates. DETAILED DESCRIPTION
[0028] definition
[0029] "Alkyl" refers to and includes a group having the specified number of carbon atoms (i.e., C1-C 10 Specific alkyl groups are those having 1 to 20 carbon atoms (“C1-C 20 More specific alkyl groups are alkyl groups having 1 to 8 carbon atoms ("C1-C8 alkyl groups"), 3 to 8 carbon atoms ("C3-C8 alkyl groups"), 1 to 6 carbon atoms ("C1-C6 alkyl groups"), 1 to 5 carbon atoms ("C1-C5 alkyl groups"), or 1 to 4 carbon atoms ("C1-C4 alkyl groups"). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; groups such as homologs and isomers of n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
[0030] As used herein, "alkenyl" refers to an unsaturated linear or branched monovalent hydrocarbon chain or combinations thereof having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C) and having a specified number of carbon atoms (i.e., C2-C 10 Alkenyl groups may be in the "cis" or "trans" configuration, or in the "E" or "Z" configuration. Specific alkenyl groups are groups having 2 to 20 carbon atoms ("C2-C 20Examples of alkenyl groups include, but are not limited to, groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, homologs and isomers thereof, and the like.
[0031] As used herein, "alkylene" refers to a residue that is identical to an alkyl group but is divalent. Specific alkylene groups are those having 1 to 6 carbon atoms ("C1-C6 alkylene"), 1 to 5 carbon atoms ("C1-C5 alkylene"), 1 to 4 carbon atoms ("C1-C4 alkylene"), or 1 to 3 carbon atoms ("C1-C3 alkylene"). Examples of alkylene groups include, but are not limited to, groups such as methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), and the like.
[0032] As used herein, "alkynyl" refers to an unsaturated linear or branched monovalent hydrocarbon chain or combinations thereof, having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C≡C) and having a specified number of carbon atoms (i.e., C2-C 10 Specific alkynyl groups are groups having 2 to 20 carbon atoms (“C2-C 20 Examples of alkynyl groups include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2-ynyl, but-3-ynyl, homologs and isomers thereof, and the like.
[0033] "Aryl" refers to and includes polyunsaturated aromatic hydrocarbon groups. Aryl can contain additional fused rings (e.g., 1 to 3 rings), including additional fused aryl, heteroaryl, cycloalkyl and / or heterocyclyl rings. In one variant, aryl contains 6 to 14 ring carbon atoms. Examples of aryl include, but are not limited to, phenyl, naphthyl, biphenyl, etc.
[0034] "Carbonyl" refers to a C=O group.
[0035] "Cycloalkyl" means and includes cyclic monovalent hydrocarbon structures which may be fully saturated, monounsaturated or polyunsaturated, but which are non-aromatic, having the specified number of carbon atoms (e.g., C1-C 10 "Cycloalkyl" refers to one to ten carbon atoms. Cycloalkyl groups may consist of one ring, such as cyclohexyl, or of multiple rings, such as adamantyl, but aryl groups are excluded. Cycloalkyl groups containing more than one ring may be fused, spirocyclic, or bridged, or a combination thereof. Preferred cycloalkyl groups are cyclic hydrocarbons having 3 to 13 ring carbon atoms. More preferred cycloalkyl groups are cyclic hydrocarbons having 3 to 8 ring carbon atoms ("C3-C8 cycloalkyl"). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, norbornyl, and the like.
[0036] "Halo" or "halogen" refers to an element of Group 17 having an atomic number of 9 to 85. Preferred halogen groups include fluorine, chlorine, bromine and iodine. When a residue is substituted with more than one halogen, it can be referred to by using a prefix corresponding to the number of halogen moieties attached, such as dihaloaryl, dihaloalkyl, trihaloaryl, etc. Referring to aryl and alkyl substituted with two ("di") or three ("tri") halogen groups, it may be, but not necessarily, the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. Alkyl groups in which each hydrogen is replaced by a halogen are referred to as "perhaloalkyl". A preferred perhaloalkyl group is trifluoroalkyl (-CF3). Similarly, "perhaloalkoxy" refers to an alkoxy group in which a halogen replaces each H in the hydrocarbon that constitutes the alkyl portion of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (-CF3).
[0037] "Heteroaryl" refers to and includes an unsaturated aromatic ring group having 1 to 10 ring carbon atoms and at least one ring heteroatom including but not limited to heteroatoms such as nitrogen, oxygen and sulfur, wherein nitrogen and sulfur atoms are optionally oxidized, and nitrogen atom is optionally quaternized. Heteroaryl can be connected to the rest of the molecule at ring carbon or ring heteroatom. Heteroaryl can include additional fused rings (for example, 1 to 3 rings), including additional fused aryl, heteroaryl, cycloalkyl and / or heterocyclic rings. The example of heteroaryl includes but is not limited to imidazolyl, pyrrolyl, pyrazolyl, 1,2,4-triazolyl, thienyl, furyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyridazinyl or pyrazinyl etc.
[0038] "Heterocycle" or "heterocyclic group" refers to a saturated or unsaturated non-aromatic group having 1 to 10 ring carbon atoms and 1 to 4 ring heteroatoms such as nitrogen, sulfur or oxygen, wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom is optionally quaternized. The heterocyclic group may have a single ring or multiple condensed rings, but heteroaryl is excluded. A heterocyclic ring containing more than one ring may be fused, spirocyclic or bridged or any combination thereof. In a condensed ring system, one or more of the condensed rings may be aryl or heteroaryl. Examples of heterocyclic groups include, but are not limited to, aziridine, azetidinyl, oxetanyl, morpholinyl, thiomorpholinyl, azepanyl, tetrahydropyranyl, dihydropyranyl, piperidinyl, piperazinyl, pyrrolidinyl, thiazolinyl, thiazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, etc.
[0039] "Oxo" refers to the moiety =0.
[0040] "CHK" refers to checkpoint kinases, including checkpoint kinase-1 (CHK-1) and checkpoint kinase-2 (CHK-2). Preferably, CHK refers to CHK-1.
[0041] Unless otherwise indicated, "optionally substituted" means that the group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents listed for the group, wherein the substituents may be the same or different. In one embodiment, the optionally substituted group has one substituent. In another embodiment, the optionally substituted group has two substituents. In another embodiment, the optionally substituted group has three substituents. In another embodiment, the optionally substituted group has four substituents. In some embodiments, the optionally substituted group has 1 to 2, 2 to 5, 3 to 5, 2 to 3, 2 to 4, 3 to 4, 1 to 3, 1 to 4, or 1 to 5 substituents.
[0042] "Pharmaceutically acceptable carrier" refers to a component of a pharmaceutical preparation other than the active ingredient that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
[0043] As used herein, "treatment" or "treating" is a method for obtaining beneficial or desired results (including clinical results). For example, beneficial or desired results include, but are not limited to, one or more of the following: reducing symptoms caused by the disease, improving the quality of life of a person suffering from the disease, reducing the dose of other drugs required to treat the disease, delaying the progression of the disease, and / or prolonging the survival of an individual. With respect to cancer or other unwanted cell proliferation, beneficial or desired results include shrinking the tumor (reducing the size of the tumor); reducing the growth rate of the tumor (such as inhibiting tumor growth); reducing the number of cancer cells; inhibiting, delaying or slowing down and preferably preventing cancer cells from infiltrating peripheral organs to a certain extent; inhibiting (slowing down and preferably preventing to a certain extent) tumor metastasis; inhibiting tumor growth; preventing or delaying the occurrence and / or recurrence of tumors; and / or alleviating one or more symptoms associated with cancer to a certain extent. In some embodiments, beneficial or desired results include preventing or delaying the occurrence and / or recurrence of, such as, unwanted cell proliferation.
[0044] As used herein, "delaying the progression of a disease" means delaying, hindering, slowing, retarding, stabilizing and / or stalling the progression of a disease (such as cancer). Such a delay may be of varying lengths of time, depending on the history of the disease and / or the individual being treated. It will be apparent to one skilled in the art that a substantial or significant delay may actually encompass prevention, in that the individual does not develop the disease. For example, the progression of an advanced cancer, such as metastasis, may be delayed.
[0045] As used herein, an "effective dose" or "effective amount" of a compound or its salt or pharmaceutical composition is an amount sufficient to produce a beneficial or desired result. For preventive use, beneficial or desired results include results such as: eliminating or reducing the risk of the disease, reducing the severity of the disease, or delaying the onset of the disease, including biochemical, histological and / or behavioral symptoms of the disease, complications that occur during the development of the disease, and intermediate pathological phenotypes. For therapeutic use, beneficial or desired results include improving, alleviating, alleviating, delaying or reducing one or more symptoms caused by the disease, improving the quality of life of those suffering from the disease, reducing the dose of other drugs required to treat the disease, such as enhancing the effect of another drug via targeting, delaying disease progression, and / or prolonging survival. With regard to cancer or other undesirable cell proliferation, an effective amount includes an amount sufficient to cause tumor shrinkage and / or reduce tumor growth rate (such as inhibiting tumor growth) or prevent or delay other undesirable cell proliferation. In some embodiments, the effective amount is an amount sufficient to delay progression. In some embodiments, the effective amount is an amount sufficient to prevent or delay occurrence and / or recurrence. An effective amount may be administered once or multiple times. In the case of cancer, an effective amount of a drug or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, delay, slow down and preferably prevent cancer cells from infiltrating peripheral organs to a certain extent; (iv) inhibit (i.e., slow down and preferably prevent to a certain extent) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay the occurrence and / or recurrence of tumors; and / or (vii) alleviate one or more symptoms associated with cancer to a certain extent. An effective dose may be administered once or multiple times. For the purposes of this disclosure, an effective dose of a compound or its salt or pharmaceutical composition is an amount sufficient to directly or indirectly complete a preventive or therapeutic treatment. It should be understood that an effective dose of a compound or its salt or pharmaceutical composition is intended to be used with or without another drug, compound or pharmaceutical composition. Therefore, in the case of administering one or more therapeutic agents, an "effective dose" may be considered, and if used in combination with one or more other drugs, a single drug may be considered to be administered in an effective amount, which may produce a desired result or achieve a desired result.
[0046] As used herein, the term "subject" is a mammal, including humans. The subject includes, but is not limited to, humans, cattle, horses, cats, dogs, rodents, or primates. In some embodiments, the subject is a human. The subject (such as a human) may have an advanced disease or a less severe disease, such as a low tumor burden. In some embodiments, the subject is in the early stages of a proliferative disease (such as cancer). In some embodiments, the subject is in the late stages of a proliferative disease (such as advanced cancer).
[0047] Reference herein to "about" a value or parameter includes (and describes) embodiments involving that value or parameter itself. For example, description referring to "about X" includes description of "X".
[0048] It should be understood that the aspects and variations described herein also include "consisting of" and / or "consisting essentially of" aspects and variations.
[0049] Compound
[0050] The present invention provides a compound of formula (IA) or a salt thereof:
[0051]
[0052] in,
[0053] Y is N or CR y ;
[0054] A is optionally replaced by 0-4 R x substituted 5- to 6-membered heteroaryl;
[0055] R x and R y are independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 7 、-NR 8 R 9 、-C(O)R 7 、-NR 7 C(O)R 8 、-C(O)OR 7 、-C(O)NR 8 R 9 , each of which is optionally substituted with oxo, halogen, -CN, -OR 10 or -NR 11 R 12 replace;
[0056] D is -(C1-C6 alkylene)OR 10 、-(C1-C6 alkylene)NR 11 R 12 , 3- to 6-membered heterocyclic group, -(C1-C6 alkylene)C3-C6 cycloalkyl group or -(C1-C6 alkylene)3- to 10-membered heterocyclic group, each of which is optionally replaced by R 2 replace;
[0057] L is -CH2-, -O-, -NH-, -N(CH3)-, -SO2-, -C(O)-, -C(O)NH- or -NHC(O)-;
[0058] R 1 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 10-membered heteroaryl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 13 、-SR 13 、-S(O)2R 13 、-S(O)2NR 14 R 15 、-NR 13 S(O)2R 14 、-NR 14 R 15 、-C(O)R 13 、-NR 13 C(O)R 14 、-NR 13 C(O)NR 14 R 15 、-C(O)OR 13 、-C(O)ONR 14 R 15 、-C(O)NR 14 R 15 、-(C1-C3 alkylene)OR 13 、-(C1-C3 alkylene)SR 13 、-(C1-C3 alkylene)S(O)2R 13 、-(C1-C3 alkylene)S(O)2NR 14 R 15 、-(C1-C3 alkylene)NR 13 S(O)2R 14 、-(C1-C3 alkylene)NR 14 R 15 、-(C1-C3 alkylene)C(O)R 13 、-(C1-C3 alkylene)NR 13 C(O)R 14 、-(C1-C3 alkylene)NR 13 C(O)NR 14 R 15 、-(C1-C3 alkylene)C(O)OR 13 、-(C1-C3 alkylene)C(O)ONR 14 R 15 , -(C1-C3 alkylene)(C3-C8 cycloalkyl) or -(C1-C3 alkylene)(3-10-membered heterocyclyl); wherein R 1 Optionally R 3 replace;
[0059] R 2 is oxo, C2-C6 alkenyl, C2-C6 alkynyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, -OR 16 、-SR 16 、-S(O)2R 16 、-S(O)2NR 17 R 18 、-NR 16 S(O)2R 17 、-NR 17 R 18 、-C(O)R 16 、-NR 16 C(O)R 17 、-C(O)OR 16 , or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2;
[0060] R 3 is oxo, C2-C6 alkenyl, C2-C6 alkynyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, -OR 16 、-SR 16 、-S(O)2R 16 、-S(O)2NR 17 R 18 、-NR 16 S(O)2R 17 、-NR 17 R 18 、-C(O)R 16 、-NR 16 C(O)R 17 、-C(O)OR 16 , C3-C6 cycloalkyl, C6 aryl, 5- to 6-membered heteroaryl, 3- to 6-membered heterocyclyl, or C1-C6 alkyl optionally substituted with oxo, -OH, halogen, or -NH2;
[0061] Each R 7 , R 8 and R 9 is independently hydrogen or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2;
[0062] R 10 is hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl or 3- to 10-membered heterocyclyl, each of which is optionally replaced by R 2 replace;
[0063] Each R 11 and R 12are independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl or 3- to 10-membered heterocyclyl, each of which is optionally replaced by R 2 replace;
[0064] or R 11 and R 12 Together with the atoms to which they are attached, they form an optionally R 2 substituted 3- to 6-membered heterocyclyl;
[0065] Each R 13 , R 14 and R 15 R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, -(C1-C3 alkylene)C3-C6 cycloalkyl, -(C1-C3 alkylene)3- to 6-membered heterocyclyl or -(C1-C3 alkylene)5- to 6-membered heteroaryl, wherein R 13 , R 14 and R 15 Each of the above is independently optionally substituted by oxo, C2-C6 alkenyl, C2-C6 alkynyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, -OR 16 、-SR 16 、-S(O)2R 16 、-S(O)2NR 17 R 18 、-NR 16 S(O)2R 17 、-NR 17 R 18 、-C(O)R 16 、-NR 16 C(O)R 17 、-C(O)OR 16 or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2;
[0066] or R 14 and R 15 Together with the atoms to which they are attached, they form a 3- to 6-membered heterocyclyl optionally substituted with oxo, OH or halogen, or C1-C6 alkyl optionally substituted with oxo, -OH, halogen or -NH2;
[0067] Each R 16 , R 17 and R 18are independently hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, C6 aryl, 5- to 6-membered heteroaryl, 3- to 6-membered heterocyclyl, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with oxo, -OH, halogen, or -NH2; and
[0068] or R 17 and R 18 Together with the atoms to which they are attached they form a 3- to 6-membered heterocyclyl optionally substituted with oxo, -OH, halogen or -NH2, or C1-C6 alkyl optionally substituted with oxo, -OH, halogen or -NH2.
[0069] In some embodiments, the compound of formula (IA) is a compound of formula (I) or a salt thereof:
[0070]
[0071] in,
[0072] Y is N or CR y ;
[0073] A is optionally replaced by 0-4 R x substituted 5- to 6-membered heteroaryl;
[0074] R x and R y are independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 7 、-NR 8 R 9 、-C(O)R 7 、-NR 7 C(O)R 8 、-C(O)OR 7 、-C(O)NR 8 R 9 , each of which is optionally substituted with oxo, halogen, -CN, -OR 10 or -NR 11 R 12 replace;
[0075] D is -(C1-C6 alkylene)OR 10 、-(C1-C6 alkylene)NR 11 R 12 , -(C1-C6 alkylene)C3-C6 cycloalkyl or -(C1-C6 alkylene)3- to 10-membered heterocyclic group, each of which is optionally replaced by R 2 replace;
[0076] L is -CH2-, -O-, -NH-, -N(CH3)-, -SO2-, -C(O)-, -C(O)NH- or -NHC(O)-;
[0077] R 1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 6-membered heteroaryl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 13 、-SR 13 、-S(O)2R 13 、-S(O)2NR 14 R 15 、-NR 13 S(O)2R 14 、-NR 14 R 15 、-C(O)R 13 、-NR 13 C(O)R 14 、-NR 13 C(O)NR 14 R 15 、-C(O)OR 13 、-C(O)ONR 14 R 15 、-C(O)NR 14 R 15 、-(C1-C3 alkylene)OR 13 、-(C1-C3 alkylene)SR 13 、-(C1-C3 alkylene)S(O)2R 13 、-(C1-C3 alkylene)S(O)2NR 14 R 15 、-(C1-C3 alkylene)NR 13 S(O)2R 14 、-(C1-C3 alkylene)NR 14 R 15 、-(C1-C3 alkylene)C(O)R 13 、-(C1-C3 alkylene)NR 13 C(O)R 14 、-(C1-C3 alkylene)NR 13 C(O)NR 14 R 15 、-(C1-C3 alkylene)C(O)OR 13 、-(C1-C3 alkylene)C(O)ONR 14 R 15, -(C1-C3 alkylene)(C3-C8 cycloalkyl) or -(C1-C3 alkylene)(3-10-membered heterocyclyl); wherein R 1 Optionally R 3 replace;
[0078] Each R 2 and R 3 are independently oxo, C2-C6 alkenyl, C2-C6 alkynyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, -OR 16 、-SR 16 、-S(O)2R 16 、-S(O)2NR 17 R 18 、-NR 16 S(O)2R 17 、-NR 17 R 18 、-C(O)R 16 、-NR 16 C(O)R 17 、-C(O)OR 16 , or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2;
[0079] Each R 7 , R 8 and R 9 is independently hydrogen or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2;
[0080] R 10 is hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl or 3- to 10-membered heterocyclyl, each of which is optionally replaced by R 2 replace;
[0081] Each R 11 and R 12 are independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl or 3- to 10-membered heterocyclyl, each of which is optionally replaced by R 2 replace;
[0082] or R 11 and R 12 Together with the atoms to which they are attached, they form an optionally R 2 substituted 3- to 6-membered heterocyclyl;
[0083] Each R 13 , R 14 and R 15are independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6 aryl, or 5- to 6-membered heteroaryl, wherein R 13 , R 14 and R 15 Each of the above is independently optionally substituted by oxo, C2-C6 alkenyl, C2-C6 alkynyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, -OR 16 、-SR 16 、-S(O)2R 16 、-S(O)2NR 17 R 18 、-NR 16 S(O)2R 17 、-NR 17 R 18 、-C(O)R 16 、-NR 16 C(O)R 17 、-C(O)OR 16 or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2;
[0084] or R 14 and R 15 Together with the atoms to which they are attached, they form a 3- to 6-membered heterocyclyl optionally substituted with oxo, OH or halogen, or C1-C6 alkyl optionally substituted with oxo, -OH, halogen or -NH2;
[0085] Each R 16 , R 17 and R 18 are independently hydrogen, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkyl optionally substituted with oxo, -OH, halogen, or -NH2; and
[0086] or R 17 and R 18 Together with the atoms to which they are attached they form a 3- to 6-membered heterocyclyl optionally substituted with oxo, -OH, halogen or -NH2, or C1-C6 alkyl optionally substituted with oxo, -OH, halogen or -NH2.
[0087] In some embodiments of the compound of Formula (IA), Y is N. In some embodiments of the compound of Formula (IA), Y is CR y In some embodiments of the compound of Formula (IA), when R y When is hydrogen, Y is CH.
[0088] In some embodiments of the compound of Formula (IA), R yis selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 7 、-NR 8 R 9 、-C(O)R 7 、-NR 7 C(O)R 8 、-C(O)OR 7 、-C(O)NR 8 R 9 , each of which is optionally substituted with oxo, halogen, -CN, -OR 10 or -NR 11 R 12 In some embodiments of the compound of Formula (IA), R y In some embodiments of the compound of Formula (IA), R y is optionally substituted with oxo, halogen, CN, -OR 10 or -NR 11 R 12 In some embodiments of the compound of Formula (IA), R y is optionally substituted with oxo, halogen, CN, -OR 10 or -NR 11 R 12 In some embodiments of the compound of Formula (IA), R y is optionally substituted with oxo, halogen, CN, -OR 10 or -NR 11 R 12 In some embodiments of the compound of Formula (IA), R y In some embodiments of the compound of Formula (IA), R y In some embodiments of the compound of Formula (IA), R y is C1-C6 alkoxy. In some embodiments of the compound of formula (IA), R y is C1-C6 haloalkoxy. In some embodiments of the compound of formula (IA), R y is C1-C6 haloalkyl. In some embodiments of the compound of formula (IA), R y For-OR 7 In some embodiments of the compound of Formula (IA), R y For-NR 8 R 9 In some embodiments of the compound of Formula (IA), Ry -C(O)R 7 In some embodiments of the compound of Formula (IA), R y For-NR 7 C(O)R 8 In some embodiments of the compound of Formula (IA), R y -C(O)OR 7 In some embodiments of the compound of Formula (IA), R y -C(O)NR 8 R 9 In some embodiments of the compound of Formula (IA), R y Selected from hydrogen, C1-C6 alkyl, -CN, halogen, -OR 7 or -NR 8 R 9 In some embodiments of the compound of Formula (IA), R y is hydrogen, methyl, Cl or F. In some embodiments of the compound of Formula (IA), R y In some embodiments of the compound of Formula (IA), R y In some embodiments of the compound of Formula (IA), R y In some embodiments of the compound of Formula (IA), R y For F.
[0089] In some embodiments of the compound of Formula (IA), CR y For CH.
[0090] In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x Substituted 5-membered heteroaryl.
[0091] In some embodiments of the compound of Formula (IA), A is a 5-membered heteroaryl selected from imidazolyl, pyrrolyl, pyrazolyl, triazolyl, thienyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl or oxadiazolyl, each of which is optionally substituted by 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R xIn some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x Substituted isoxazolyl.
[0092] In some embodiments of the compound of Formula (IA), A is a 6-membered heteroaryl selected from pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl, each of which is optionally substituted by 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x Substituted pyrazinyl.
[0093] In some embodiments of the compound of Formula (IA), R x is C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 7 、-NR 8 R 9 、-C(O)R 7 、-NR 7 C(O)R 8 、-C(O)OR 7 、-C(O)NR 8 R 9 , each of which is optionally substituted with oxo, halogen, -CN, -OR 10 or -NR 11 R 12 In some embodiments of the compound of Formula (IA), R x C1-C6 alkyl, -CN, halogen, -OR 7 、-NR 8 R 9 、-NR 7 C(O)R 8 or -C(O)NR 8 R 9 In some embodiments of the compound of Formula (IA), Rx is C1-C6 alkyl. In some embodiments of the compound of formula (IA), R x In some embodiments of the compound of Formula (IA), R x In some embodiments of the compound of Formula (IA), R x For-OR 7 In some embodiments of the compound of Formula (IA), R x For-NR 8 R 9 In some embodiments of the compound of Formula (IA), R x For-NR 7 C(O)R 8 In some embodiments of the compound of Formula (IA), R x -C(O)NR 8 R 9 .
[0094] In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x substituted imidazolyl, pyrrolyl, pyrazolyl, triazolyl, thienyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl or oxadiazolyl, wherein R x is C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 7 、-NR 8 R 9 、-C(O)R 7 、-NR 7 C(O)R 8 、-C(O)OR 7 、-C(O)NR 8 R 9 , each R x Optionally substituted with oxo, halogen, CN, -OR 10 or -NR 11 R 12 In some embodiments of the compound of Formula (IA), A is optionally substituted by CN-, -C(O)NR 8 R 9 , C1-C6 haloalkyl, C1-C6 alkyl optionally substituted by halogen, or -OR 10 In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R xsubstituted imidazolyl, pyrrolyl, pyrazolyl, triazolyl, thienyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl or oxadiazolyl, wherein R x Selected from -CN, -CONH2, -CH3, -CF3, -CH2CF3 or -CH2OH.
[0095] In some embodiments of the compound of Formula (IA), A is optionally substituted with 0-4 R x Substituted pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein R x is C1-C6 alkyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 7 、-NR 8 R 9 、-C(O)R 7 、-NR 7 C(O)R 8 、-C(O)OR 7 、-C(O)NR 8 R 9 , each R x Optionally substituted with oxo, halogen, -CN, OR 10 or -NR 11 R 12 In some embodiments of the compound of Formula (IA), A is optionally substituted with -CN, -C(O)NR 8 R 9 , C1-C6 haloalkyl, C1-C6 alkyl optionally substituted by halogen, or -OR 10 Substituted pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl. In some embodiments of the compound of formula (IA), A is pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl optionally substituted with -CN, -CONH2, -CH3, -CF3, -CH2CF3 or -CH2OH.
[0096] In some embodiments of the compound of Formula (IA), A is selected from imidazolyl, pyrrolyl, pyrazolyl, triazolyl, thienyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl substituted with -CN, -CONH2, -CH3, -CF3, -CH2CF3 or -CH2OH.
[0097] In some embodiments of the compound of Formula (IA), R x In some embodiments of the compound of Formula (IA), R x In some embodiments of the compound of Formula (IA), Rx In some embodiments of the compound of Formula (IA), R x In some embodiments of the compound of formula (IA), R x is -CH2CF3. In some embodiments of the compound of Formula (IA), R x It is -CH2OH.
[0098] In some embodiments of the compound of Formula (IA), A is pyrazolyl substituted with -CH3. In some embodiments of the compound of Formula (IA), A is pyrazinyl substituted with -CN.
[0099] In some embodiments of the compound of Formula (IA), A is selected from
[0100]
[0101] The wavy line indicates the point of attachment to the rest of the molecule.
[0102] In some embodiments of the compound of Formula (IA), A is selected from
[0103]
[0104] The wavy line indicates the point of attachment to the rest of the molecule.
[0105] In some embodiments of the compound of Formula (IA), A is.
[0106] In some embodiments of the compound of Formula (IA), A is
[0107] In some embodiments of the compound of Formula (IA), A is
[0108] In some embodiments of the compound of Formula (IA), A is
[0109] In some embodiments of the compound of Formula (IA), D is -(C1-C6 alkylene)OR 10 、-(C1-C6 alkylene)NR 11 R 12 , 3- to 6-membered heterocyclic group, -(C1-C6 alkylene)C3-C6 cycloalkyl group or -(C1-C6 alkylene)3- to 10-membered heterocyclic group, each of which is optionally replaced by R 2 In some embodiments of the compound of Formula (IA), D is optionally replaced by R 2 Substituted -(C1-C6 alkylene)OR 10In some embodiments of the compound of Formula (IA), D is optionally replaced by R 2 Substituted-(C1-C6 alkylene)NR 11 R 12 In some embodiments of the compound of Formula (IA), D is optionally replaced by R 2 In some embodiments of the compound of Formula (IA), D is optionally substituted with R 2 In some embodiments of the compound of formula (IA), D is optionally replaced by R 2 Substituted -(C1-C6 alkylene) 3- to 10-membered heterocyclic group.
[0110] In some embodiments of the compound of Formula (IA), the C1-C6 alkylene of D (wherein D is cycloalkyl-(C1-C6 alkylene) as disclosed herein in Formula (IA) OR 10 、-(C1-C6 alkylene)NR 11 R 12 , -(C1-C6 alkylene)C3-C6 or -(C1-C6 alkylene)3- to 10-membered heterocyclyl) is substituted or unsubstituted. In some embodiments of the compound of formula (IA), C1-C6 alkylene is a linear alkylene, such as -CH2-, -CH2-CH2- or -CH2-CH2-CH2-. In some embodiments of the compound of formula (IA), C1-C6 alkylene is a branched alkylene, such as -CH(CH3)-, -C(CH3)2-, -CH(CH3)-CH2- or -CH2-CH(CH3)-. For example, in certain embodiments, -(C1-C6 alkylene)NR 11 R 12 is -CH(CH3)CH2-N(CH3)2. For example, in certain embodiments, -(C1-C6 alkylene)NR 11 R 12 It is -CH2-CH2-N(CH3)2 or -CH2-CH2-CH2-N(CH3)2.
[0111] In some embodiments of the compound of Formula (IA), D is selected from
[0112]
[0113]
[0114] The wavy line indicates the point of attachment to the rest of the molecule.
[0115] In some embodiments of the compound of Formula (IA), D is selected from
[0116] The wavy line indicates the point of attachment to the rest of the molecule.
[0117] In some embodiments of the compound of Formula (IA), D is
[0118] In some embodiments of the compound of Formula (IA), D is
[0119] In some embodiments of the compound of Formula (IA), D is
[0120] In some embodiments of the compound of Formula (IA), D is
[0121] In some embodiments of compounds of formula (IA), L is -CH2-, -O-, -NH-, -N(CH3)-, -SO2-, -C(O)-, -C(O)NH-, or -NHC(O)-. In some embodiments of compounds of formula (IA), L is -CH2-. In some embodiments of compounds of formula (IA), L is -O-. In some embodiments of compounds of formula (IA), L is -NH-. In some embodiments of compounds of formula (IA), L is -N(CH3)-. In some embodiments of compounds of formula (IA), L is -SO2-. In some embodiments of compounds of formula (IA), L is -C(O)-. In some embodiments of compounds of formula (IA), L is -C(O)NH-. In some embodiments of compounds of formula (IA), L is -NHC(O)-.
[0122] In some embodiments of the compound of Formula (IA), L is -NH-.
[0123] In some embodiments of the compound of Formula (IA), L is -O-.
[0124] In some embodiments of the compound of Formula (IA), R 1 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 10-membered heteroaryl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 13 、-SR 13 、-S(O)2R 13 、-S(O)2NR 14 R 15 、-NR 13 S(O)2R14 、-NR 14 R 15 、-C(O)R 13 、-NR 13 C(O)R 14 、-NR 13 C(O)NR 14 R 15 、-C(O)OR 13 、-C(O)ONR 14 R 15 、-C(O)NR 14 R 15 、-(C1-C3 alkylene)OR 13 、-(C1-C3)alkylene)SR 13 、-(C1-C3 alkylene)S(O)2R 13 、-(C1-C3 alkylene)S(O)2NR 14 R 15 、-(C1-C3 alkylene)NR 13 S(O)2R 14 、-(C1-C3 alkylene)NR 14 R 15 、-(C1-C3 alkylene)C(O)R 13 、-(C1-C3 alkylene)NR 13 C(O)R 14 、-(C1-C3 alkylene)NR 13 C(O)NR 14 R 15 、-(C1-C3 alkylene)C(O)OR 13 、-(C1-C3 alkylene)C(O)ONR 14 R 15 , -(C1-C3 alkylene)(C3-C8 cycloalkyl) or -(C1-C3 alkylene)(3-10-membered heterocyclyl); wherein each R 1 Optionally R 3 In some embodiments of the compound of Formula (IA), R 1 In some embodiments of the compound of Formula (IA), R 1 is optionally R 3 In some embodiments of the compound of Formula (IA), R 1 is methyl, ethyl, isopropyl, tert-butyl optionally substituted with -F, -CN, -OH or -CH3. In some embodiments of the compound of formula (IA), R 1 is optionally R 3In some embodiments of the compound of Formula (IA), R 1 In some embodiments of the compound of Formula (IA), R 1 is optionally R 3 In some embodiments of the compound of Formula (IA), R 1 is ethynyl, propynyl, butynyl, optionally substituted with -CH3, -OH or -OCH3. In some embodiments of the compound of formula (IA), R 1 is optionally R 3 In some embodiments of the compound of Formula (IA), R 1 In some embodiments of the compound of Formula (IA), R 1 is optionally R 3 In some embodiments of the compound of Formula (IA), R 1 is optionally R 3 In some embodiments of the compound of Formula (IA), R 1 is optionally R 3 In some embodiments of the compound of Formula (IA), R 1 is pyrazolyl optionally substituted with methyl, isopropyl or cyclopropyl. In some embodiments of the compound of Formula (IA), R 1 In some embodiments of the compound of Formula (IA), R 1 In some embodiments of the compound of Formula (IA), R 1 is C1-C6 alkoxy. In some embodiments of the compound of formula (IA), R 1 is C1-C6 haloalkoxy. In some embodiments of the compound of formula (IA), R 1 is C1-C6 haloalkyl. In some embodiments of the compound of formula (IA), R 1 In some embodiments of the compound of formula (IA), R 1 OR 13 In some embodiments of the compound of Formula (IA), R 1 In some embodiments of the compound of formula (IA), R 1 For-SR 13 In some embodiments of the compound of Formula (IA), R 1 is -S(O)2R13 In some embodiments of the compound of Formula (IA), R 1 -S(O)2NR 14 R 15 In some embodiments of the compound of Formula (IA), R 1 For-NR 13 S(O)2R 14 In some embodiments of the compound of Formula (IA), R 1 For-NR 14 R 15 In some embodiments of the compound of Formula (IA), R 1 -C(O)R 13 In some embodiments of the compound of Formula (IA), R 1 For-NR 13 C(O)R 14 In some embodiments of the compound of Formula (IA), R 1 For-NR 13 C(O)NR 14 R 15 In some embodiments of the compound of Formula (IA), R 1 -C(O)OR 13 In some embodiments of the compound of Formula (IA), R 1 is -C(O)OCH3. In some embodiments of the compound of Formula (IA), R 1 -C(O)ONR 14 R 15 In some embodiments of the compound of Formula (IA), R 1 -C(O)NR 14 R 15 In some embodiments of the compound of Formula (IA), R 1 It is -C(O)NH2.
[0125] In some embodiments of the compound of Formula (IA), R 1 -C(O)NR 14 R 15 , where R 14 and R 15 is independently selected from hydrogen, C1-C6 alkyl and C3-C6 cycloalkyl. In some embodiments of the compound of formula (IA), R 1 -C(O)NR 14 R 15 , where R 14 and R 15 is independently selected from hydrogen and C1-C6 alkyl. In some embodiments of the compound of Formula (IA), R 1-C(O)NR 14 R 15 , where R 14 and R 15 is independently selected from hydrogen and C3-C6 cycloalkyl. In some embodiments of the compound of Formula (IA), R 1 -C(O)NR 14 R 15 , where R 14 and R 15 is independently selected from hydrogen, methyl and cyclopropyl. In some embodiments of the compound of Formula (IA), R 1 -C(O)NR 14 R 15 , where R 14 and R 15 In some embodiments of the compound of Formula (IA), R 1 -C(O)NR 14 R 15 , where R 14 is hydrogen and R 15 In some embodiments of the compound of Formula (IA), R 1 -C(O)NR 14 R 15 , where R 14 and R 15 In some embodiments of the compound of Formula (IA), R 1 -C(O)NR 14 R 15 , where R 14 is hydrogen and R 15 It is cyclopropyl.
[0126] In some embodiments of the compound of Formula (IA), R 1 Selected from hydrogen, -CH3,
[0127]
[0128] The wavy line indicates the point of attachment to the rest of the molecule.
[0129] In some embodiments of the compound of Formula (IA), R 1 For hydrogen.
[0130] In some embodiments of the compound of Formula (IA), R 1 It is -CH3.
[0131] In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for In some embodiments of the compound of Formula (IA), R 1 for
[0132] In some embodiments of the compound of Formula (IA), R 1 for
[0133] In some embodiments of the compound of Formula (IA), R 1 for
[0134] In some embodiments of the compound of Formula (IA), R 1 for
[0135] In some embodiments of the compound of Formula (IA), R 1 for
[0136] In some embodiments of the compound of Formula (IA), R 1 for
[0137] It should be understood that A, D, Y, L and R 1Each description can be independently associated with A, D, Y, L and R 1 each described combination as if each combination were specifically and individually listed.
[0138] In some embodiments of the compound of Formula (IA), Y is selected from N or CR y In some embodiments of the compound of Formula (IA), Y is N. In some embodiments of the compound of Formula (IA), Y is CR y , where R y Selected from hydrogen, C1-C6 alkyl, -CN, halogen, -OR 7 or -NR 8 R 9 In some embodiments of the compound of Formula (IA), Y is CH. In some embodiments of the compound of Formula (IA), Y is CH and A is optionally substituted by 0-4 R x In some embodiments of the compound of formula (IA), Y is CH and A is selected from pyrazolyl, pyridinyl or pyrazinyl substituted with -CH3 or CN. In some embodiments of the compound of formula (IA), Y is CH and A is selected from In some embodiments of the compound of Formula (IA), Y is CH and A is In some embodiments of the compound of Formula (IA), Y is CH and A is In some embodiments of the compound of Formula (IA), Y is CH and A is In some embodiments of the compound of Formula (IA), Y is CH and A is
[0139] In some embodiments of the compound of Formula (IA), Y is CH, A is and L is selected from -NH- or -O-. In some embodiments of the compound of Formula (IA), Y is CH, A is and L is -NH-. In some embodiments of the compound of Formula (IA), Y is CH, A is And L is -O-.
[0140] In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O- and D is selected from 3- to 6-membered heterocyclyl or -(C1-C6 alkylene)3- to 10-membered heterocyclyl, each of which is optionally replaced by R 2 In some embodiments of the compound of formula (IA), Y is CH, A is L is -O- and D is selected from In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O- and D is In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O- and D is In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O- and D is In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O- and D is
[0141] In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O-, D is And R 1 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6 aryl, 5- to 10-membered heteroaryl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -C(O)NR 14 R 15 , where each R 1 Optionally R 3 In some embodiments of the compound of formula (IA), Y is CH, A is L is -O-, D is And R 1 Selected from hydrogen, -CH3,
[0142] In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O-, D is And R 1 In some embodiments of the compound of formula (IA), Y is CH, A is L is -O-, D is And R 1 for In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O-, D is And R 1 for In some embodiments of the compound of Formula (IA), Y is CH, A is L is -O-, D is And R 1 for
[0143] In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH- and D is selected from 3- to 6-membered heterocyclyl or -(C1-C6 alkylene)3- to 10-membered heterocyclyl, each of which is optionally replaced by R 2 In some embodiments of the compound of formula (IA), Y is CH, A is L is -NH- and D is selected from In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH- and D is In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH- and D is In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH- and D is In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH- and D is
[0144] In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH-, D is And R 1 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C6 aryl, 5- to 10-membered heteroaryl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -C(O)NR 14 R 15 , where each R 1 Optionally R 3 In some embodiments of the compound of formula (IA), Y is CH, A is L is -NH-, D is And R 1 Selected from hydrogen, -CH3, In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH-, D is And R 1 In some embodiments of the compound of formula (IA), Y is CH, A is L is -NH-, D is And R 1 for In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH-, D is And R 1 for In some embodiments of the compound of Formula (IA), Y is CH, A is L is -NH-, D is And R 1 for
[0145] In some embodiments, the compound of formula (IA) is a compound of formula (II) or a salt thereof,
[0146]
[0147] Among them, A, D, L, R 1 and R y As defined for formula (IA).
[0148] In some embodiments, the compound of formula (IA) is any one of the compounds of formula (IIa-1) to (IIa-10) or a salt thereof,
[0149]
[0150]
[0151] Among them, D, L, R 1 , R x and R y As defined for formula (IA).
[0152] In some embodiments, the compound of formula (IA) is any one of the compounds of formula (IIb-1) to (IIb-20) or a salt thereof,
[0153]
[0154]
[0155]
[0156] Among them, D, L, R 1 , R x and R y As defined for formula (IA).
[0157] In some embodiments, the compound of formula (IA) is a compound of formula (III) or a salt thereof,
[0158]
[0159] Among them, A, D, L and R 1 As defined for formula (IA).
[0160] In some embodiments, the compound of formula (IA) is any one of the compounds of formula (IIIa-1) to (IIIa-10) or a salt thereof,
[0161]
[0162]
[0163] Among them, D, L, R 1 and R x As defined for formula (IA).
[0164] In some embodiments, the compound of formula (IA) is a compound of any one of formulas (IIIb-1) to (IIIb-20) or a salt thereof,
[0165]
[0166]
[0167]
[0168] Among them, D, L, R 1 and R x As defined for formula (IA).
[0169] In some embodiments, the compound of formula (IA) is a compound of formula (IV) or a salt thereof,
[0170]
[0171] Among them, A, D, L, R y and R 15 As defined for formula (IA).
[0172] In some embodiments, the compound of formula (IA) is any one of the compounds of formula (IVa-1) to (IVa-15) or a salt thereof,
[0173]
[0174]
[0175]
[0176] Among them, D, L, R 15 , R x and R y As defined for formula (IA).
[0177] Also provided are salts of the compounds mentioned herein, such as pharmaceutically acceptable salts.The present invention also includes any or all stereochemical forms of the compounds, including any enantiomeric or diastereomeric forms, as well as any tautomeric or other forms.
[0178] On the one hand, the compound described in detail herein can be in purified form, and compositions containing compounds in purified form are described in detail herein. Compositions such as compositions of substantially pure compounds are provided comprising compounds or their salts as described in detail herein. In some embodiments, compositions comprising compounds or their salts as described in detail herein are in substantially pure form. Unless otherwise indicated, "substantially pure" refers to compositions containing no more than 35% impurities, wherein impurities represent compounds other than compounds or their salts constituting most of the composition. In some embodiments, compositions of substantially pure compounds or their salts are provided, wherein the compositions contain no more than 25%, 20%, 15%, 10% or 5% impurities. In some embodiments, compositions of substantially pure compounds or their salts are provided, wherein the compositions contain no more than 3%, 2%, 1% or 0.5% impurities.
[0179] Representative compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) are listed in Table 1 and Table 2. It should be understood that individual enantiomers and diastereomers are included in the general compound structures shown in Table 1 and Table 2. Examples of specific synthetic methods for preparing the compounds of Table 1 are provided herein.
[0180] Table 1: Compounds
[0181]
[0182]
[0183]
[0184]
[0185]
[0186] The compounds shown in Table 2 can be prepared in a manner analogous to the techniques associated with the preparation of the compounds given in Table 1 and accordingly using appropriately analogous starting materials and by employing the general synthetic schemes shown below.
[0187] Table 2: Compounds
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195]
[0196]
[0197]
[0198]
[0199]
[0200]
[0201]
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220] In some embodiments, provided herein are compounds described in Table 1 and Table 2 or salts thereof, and uses thereof.
[0221] Where applicable, the embodiments and variations described herein apply to compounds of any formula detailed herein.
[0222] Representative examples of compounds detailed herein are described herein, including intermediates and final compounds according to the present disclosure. It should be understood that in one aspect, any compound can be used in the methods detailed herein, including intermediate compounds that can be isolated and administered to an individual where applicable.
[0223] Even if salts are not described, the compounds described herein may exist in the form of salts, and it should be understood that the disclosure encompasses all salts and solvates of the compounds described herein, as well as non-salt and non-solvate forms of the compounds known to those skilled in the art. In some embodiments, the salts of the compounds provided herein are pharmaceutically acceptable salts. In the case of one or more tertiary amine moieties in the compound, N-oxides are also provided and described.
[0224] Where any compound described herein may exist in tautomeric forms, each and every tautomeric form is intended, even though only one or a few tautomeric forms may be explicitly described. The specifically described tautomeric form may or may not be the predominant form in solution or when used according to the methods described herein.
[0225] The present disclosure also includes any or all stereochemical forms, including any enantiomeric or diastereomeric forms of the compound. The structure or name is intended to cover all possible stereoisomers of the compound described, and each unique stereoisomer has a compound number with suffixes such as "a", "b". All forms of the compound are also encompassed in the present invention, such as crystalline or non-crystalline forms of the compound. It is also intended to include compositions of the compounds of the present invention, such as compositions of substantially pure compounds, including their specific stereochemical forms, or compositions of mixtures of the compounds of the present invention in any ratio, including two or more stereochemical forms, such as racemic or non-racemic mixtures.
[0226] The present invention also relates to isotopically labeled and / or isotopically enriched forms of the compounds described herein. The compounds herein may contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. In some embodiments, the compounds are isotopically labeled, such as isotopically labeled compounds of formula (IA) or variants thereof described herein, in which a portion of one or more atoms is replaced by an isotope of the same element. Exemplary isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 O. 17 O. 32 P. 35 S. 18 F. 36 Cl. Certain isotopically labeled compounds (e.g. 3 H and 14 C) can be used for compound or substrate tissue distribution studies. Heavier isotopes such as deuterium ( 2 P) may offer certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and thus may be preferred in some circumstances.
[0227] Isotopically labeled compounds of the present invention can generally be prepared by standard methods and techniques known to those skilled in the art or by procedures analogous to those described in the accompanying examples, by substituting an appropriate isotopically labeled reagent for the corresponding non-labeled reagent.
[0228] The present invention also includes any or all metabolites of any of the compounds. Metabolites can include any chemical species produced by the biotransformation of any of the compounds, such as intermediates and metabolic products of the compounds, such as those produced in vivo after administration to humans.
[0229] Provided are articles of manufacture comprising a compound described herein, or a salt or solvate thereof, in a suitable container. The container may be a vial, a jar, an ampoule, a prefilled syringe, an intravenous bag, and the like.
[0230] Preferably, the compounds detailed herein are orally bioavailable. However, the compounds may also be formulated for parenteral (eg, intravenous) administration.
[0231] One or more compounds described herein can be used to prepare a drug by combining one or more compounds as active ingredients with a pharmaceutically acceptable carrier known in the art. Depending on the therapeutic form of the drug, the carrier can be in various forms. In one variation, the manufactured drug is used in any method disclosed herein, for example, for treating cancer.
[0232] General synthetic scheme
[0233] The compounds of the present invention can be prepared by a number of methods generally described below and more specifically described in the Examples below, such as the schemes provided in the Examples below. In the following process descriptions, when symbols are used in the depicted formulas, it should be understood that these symbols represent those groups associated with the structural formulae herein as described above.
[0234] If it is desired to obtain a specific enantiomer of a compound, this can be achieved by the corresponding mixture of enantiomers using any suitable conventional procedure for separating or splitting enantiomers. Therefore, for example, diastereomeric derivatives can be produced by the reaction of a mixture of enantiomers (e.g., racemate) with a suitable chiral compound. The diastereoisomers can then be separated by any convenient means, such as by crystallization and recovery of the desired enantiomer. In another method of separation, chiral high performance liquid chromatography can be used to separate the racemate. Alternatively, if desired, a specific enantiomer can be obtained by using a suitable chiral intermediate in one of the methods.
[0235] Where it is desired to obtain a specific isomer of a compound or to otherwise purify a reaction product, chromatography, recrystallization and other conventional separation procedures may also be used for the intermediates or final products.
[0236] Solvates and / or polymorphs of the compounds provided herein or their pharmaceutically acceptable salts are also contemplated. Solvates contain stoichiometric or non-stoichiometric amounts of solvents and are typically formed during the crystallization process. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Polymorphs include different crystal packing arrangements of compounds composed of the same elements. Polymorphs typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, optical and electrical properties, stability and / or solubility. Various factors such as recrystallization solvents, crystallization rates, and storage temperatures may result in a single crystal form being dominant.
[0237] In some embodiments, the compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) can be synthesized according to Scheme-1 to Scheme-8.
[0238] Solution 1:
[0239]
[0240] wherein A and D are as defined in formula (IA).
[0241] Option 2:
[0242]
[0243] Among them, A, D and R 1 As defined in formula (IA). Scheme 3:
[0244]
[0245] Among them, A, D and R 1 As defined in formula (IA). Scheme 4:
[0246]
[0247] wherein A and D are as defined in formula (IA).
[0248] Solution 5:
[0249]
[0250] Among them, A, D and R 1 As defined in formula (IA). Scheme 6:
[0251]
[0252] Among them, A, D and R 1 As defined in formula (IA).
[0253] Solution 7:
[0254]
[0255] Among them, A, D, L, Y and R 1 As defined in formula (IA).
[0256] Solution 8:
[0257]
[0258] Among them, A, D, L, R 14 and R 15 As defined in formula (IA).
[0259] Pharmaceutical compositions and preparations
[0260] Pharmaceutical compositions of any compound described in detail herein are encompassed in the present disclosure. Thus, the present disclosure includes pharmaceutical compositions comprising a compound as described in detail herein or a salt thereof and a pharmaceutically acceptable carrier or excipient. In one aspect, a pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid. The pharmaceutical composition can be in a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration or in a form suitable for administration by inhalation.
[0261] In one aspect, the compounds as described in detail herein can be in purified form, and compositions comprising the compounds in purified form are described in detail herein. Compositions comprising the compounds as described in detail herein or their salts are provided, such as compositions of substantially pure compounds. In some embodiments, compositions comprising the compounds as described in detail herein or their salts are in substantially pure form.
[0262] In one variation, the compounds herein are synthetic compounds prepared for administration to an individual. In another variation, compositions comprising substantially pure forms of the compounds are provided. In another variation, the disclosure encompasses pharmaceutical compositions comprising the compounds detailed herein and a pharmaceutically acceptable carrier. In another variation, methods of administering the compounds are provided. The purified forms, pharmaceutical compositions, and methods of administering the compounds are applicable to any compound or form thereof detailed herein.
[0263] The compounds or salts thereof described in detail herein can be formulated for any available delivery route, including oral, mucosal (e.g., nasal, sublingual, vaginal, oral or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery forms. The compounds or salts thereof can be formulated with a suitable carrier to provide delivery forms including, but not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, chewing gums, dispersions, suppositories, ointments, poultices (composts), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalants), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
[0264] One or more compounds or their salts as active ingredients can be combined with pharmaceutically acceptable carriers such as those mentioned above, and one or more compounds or their salts as described herein can be used to prepare preparations such as pharmaceutical preparations. Depending on the treatment form of the system (for example, transdermal patch and oral tablets), the carrier can be in various forms. In addition, the pharmaceutical preparation may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators and salts, buffers, coating agents or antioxidants for regulating osmotic pressure. The preparation comprising the compound can also include other substances with valuable therapeutic properties. Pharmaceutical preparations can be prepared by known pharmaceutical methods. Suitable preparations can be found, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, (2000) 20th edition, which is incorporated herein by reference.
[0265] The compounds as described herein can be administered to individuals in the form of commonly accepted oral compositions, such as tablets, coated tablets, and gel capsules, emulsions, or suspensions in hard or soft shells. Examples of carriers that can be used to prepare such compositions are lactose, corn starch or its derivatives, talc, stearates or their salts, etc. Acceptable carriers for gel capsules with soft shells are, for example, vegetable oils, waxes, fats, semisolid and liquid polyols, etc. In addition, the pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts, buffers, coating agents, or antioxidants for regulating osmotic pressure.
[0266] Any of the compounds described herein may be formulated in a tablet in any of the dosage forms described, for example, a compound or salt thereof as described herein may be incorporated into a tablet in an amount of about 1 mg to about 1000 mg.
[0267] Compositions comprising the compounds provided herein are also described. In one variation, the composition comprises the compound or its salt and a pharmaceutically acceptable carrier or excipient. In another variation, a composition of a substantially pure compound is provided.
[0268] How to use
[0269] The compounds and compositions described in detail herein, such as pharmaceutical compositions containing a compound of any structural formula provided herein or a salt thereof and a pharmaceutically acceptable carrier or excipient, can be used in methods of administration and treatment as provided herein. The compounds and compositions can also be used in in vitro methods, such as in vitro methods in which the compounds or compositions are administered to cells for screening purposes and / or quality control assays.
[0270] Provided herein is a method of treating a disease in a subject, comprising administering to the subject an effective amount of a compound of the invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or any embodiment, variation or aspect thereof, or a compound of the invention or one or more compounds detailed or described herein, or a pharmaceutically acceptable salt thereof. Further provided herein is a method of treating a proliferative disease in an individual, comprising administering to the individual an effective amount of a compound of the invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) or a pharmaceutically acceptable salt thereof. Also provided herein is a method of treating cancer in an individual, comprising administering to the individual an effective amount of a compound of Formula (IA) or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is administered to the individual according to the dosage and / or method of administration described herein.
[0271] Another aspect of the present invention relates to a method for treating a disease or condition associated with a checkpoint kinase. The method comprises administering an effective amount of a composition and compound of the present invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) to a patient in need of treatment for a disease or condition associated with a checkpoint kinase.
[0272] Another aspect of the present invention relates to a method for inhibiting checkpoint kinases. The method comprises administering an effective amount of a composition or compound of the present invention (collectively, a compound of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) to a patient in need thereof.
[0273] Use of the compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) in the manufacture of a medicament for treating a proliferative disease such as cancer.
[0274] Use of the compounds of the present invention (collectively, compounds of formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) in the manufacture of a medicament for treating cancer, wherein the cancer is selected from cancers such as bladder cancer, breast cancer, colon cancer, kidney cancer, epidermal cancer, liver cancer, lung cancer, esophageal cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, gastrointestinal system cancer or skin cancer, hematopoietic tumors such as leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma or Burkett's lymphoma; hematopoietic tumors of the myeloid lineage, such as acute and chronic myeloid leukemia, myelodysplastic syndrome or promyelocytic leukemia; follicular thyroid carcinoma; tumors of mesenchymal origin, such as fibrosarcoma or rhabdomyosarcoma; central or peripheral nervous system tumors, such as astrocytoma, neuroblastoma, glioma or schwannoma; melanoma; seminoma; teratoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; follicular thyroid carcinoma; Ewing's sarcoma or Kaposi's sarcoma. Use of the compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) in the manufacture of a medicament for treating cancer, wherein the cancer is a cancer characterized by defective DNA repair mechanisms or defective cell cycle.
[0275] Use of the compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) in the manufacture of a medicament for treating cancer, wherein the cancer is a p53 negative or mutated tumor.
[0276] Use of the compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) in the manufacture of a medicament for treating cancer, wherein the cancer is a MYC oncogene driven cancer.
[0277] Use of the compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) in the manufacture of a medicament for treating cancer, wherein the MYC oncogene-driven cancer is B-cell lymphoma, leukemia, neuroblastoma, breast cancer or lung cancer.
[0278] Use of the compounds of the present invention (collectively, compounds of Formula (IA), (I), (II), (IIa-1) to (IIa-10), (IIb-1) to (IIb-20), (III), (IIIa-1) to (IIIa-10), (IIIb-1) to (IIIb-20), (IV) or (IVa-1) to (IVa-15)) in the manufacture of a medicament for treating cancer, wherein the cancer is high-grade serous ovarian cancer (HGSOC), triple-negative breast cancer (TNBC) and small cell lung cancer (SCLC). CCNE1 amplification occurs in about 20% of HGSOC tumors. It is well known that CCNE1 amplification (CCNE1 amp) increases replication stress (RS) and genomic instability, leading to increased dependence on checkpoint kinase 1 (CHK-1). Therefore, CCNE1 amplification is associated with clinical response to CHK-1 inhibitors (Lee et al., Lancet Oncol. 2018 19(2), 207). Increased DNA repair and cell cycle checkpoint activation remain the main reasons for TNBC tumor resistance to chemotherapy and PARP inhibitors. Synergistic effects of CHK-1 inhibitors and PARP inhibitors were observed in TNBC with elevated RAD51 expression [2] (Mani et al., Breast Cancer Research (2019) 21: 104). CHK-1 inhibition may be particularly effective in SCLC with MYC amplification or MYC protein overexpression. CHK-1 inhibitors exhibit strong single-agent efficacy, enhance the effects of cisplatin or the PARP inhibitor olaparib, and improve the response of platinum-resistant models. (Cancer Res 2017, 77(14), 3870-3884-Sen et al.).
[0279] The compounds disclosed herein may be administered in an amount effective to treat or prevent a condition in a subject and / or prevent its progression.
[0280] Combination therapy
[0281] The compounds of the present invention may be administered simultaneously with one or more other therapeutic agents or before or after one or more other therapeutic agents. The compounds of the present invention may be administered separately by the same or different administration routes, or together with other agents in the same pharmaceutical composition.
[0282] In some embodiments, the methods described herein include an additional step of co-administering a second therapy to a subject in need thereof, such as an additional cancer therapeutic agent or an additional cancer treatment. Exemplary additional cancer therapeutic agents include, for example, in one embodiment, additional active agents are selected from, but not limited to, antimetabolites, tubulin targeting agents, DNA binders and topoisomerase II inhibitors, alkylating agents, monoclonal antibodies, hormone therapy, signal transduction inhibitors, proteasome inhibitors, DNA methyltransferases, cytokines and retinoids, hypoxia-induced DNA damaging agents, immunomodulators (e.g., CTLA-4, LAG-3, PD-1 antagonists, etc.) and monoclonal antibodies.
[0283] In some embodiments, the additional cancer therapeutic agent is a chemotherapeutic agent. Examples of chemotherapeutic agents for cancer therapy include, for example, antimetabolites (e.g., folic acid, purine and pyrimidine derivatives), alkylating agents (e.g., nitrogen mustards, nitrosoureas, platinums, alkyl sulfonates, hydrazines, triazenes, aziridines, spindle poisons, cytotoxic agents, topoisomerase inhibitors, etc.), and demethylating agents (e.g., decitabine (5-aza-deoxycytidine), zebularine (zebularine), isothiocyanates, azacitidine (5-azacytidine), 5-fluoro-2'-deoxycytidine, 5,6-dihydro-5-azacytidine, etc.). Exemplary agents include aclarubicin, actinomycin, alitretinoin, altretamine, aminopterin, aminolevulinic acid, acid, Amrubicin, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase, Atrasentan, Belotecan, Bexarotene, Bendamustine, Bleomycin, Bortezomib, Busulfan, Camptothecin, Capecitabine, Carboplatin, Carboquone, Carmofur, Carmustine, Celecoxib, Chlorambucil, Chlorambucil、Chlormethine、Cisplatin、Cladribine、Clofarabine、Crisantaspase、Cyclophosphamide、Cytarabine、Dacarbazine、Dactinomycin、Daunorubicin、Decitabine、Demecolcine、Docetaxel、Doxorubicin、Efaproxiral、Elesclomol、Elsamitrucin、Enocitabine, Epirubicin, Estramustine, Etoglucid, Etoposide, Floxuridine, Fludarabine, Fluorouracil (5FU), Fotemustine, Gemcitabine, Gliadel implant, Hydroxycarbamide, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Irofulven, Ixabepilone, Larotaxel, Leucovorin, Liposomal doxorubicin doxorubicin, Liposomal daunorubicin, Lonidamine, Lomustine, Lucanthone, Mannosulfan, Masoprocol, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methyl aminolevulinate aminolevulinate、Mitobronitol、Mitoguazone、Mitotane、Mitomycin、Mitoxantrone、Nedaplatin、Nimustine、Oblimersen、Omacetaxine、Ortataxel、Oxaliplatin、Paclitaxel、Pegaspargase、Pemetrexed、Pentostatin、Pirarubicin、Pixantrone、Plicamycin、Porfimer sodium、Prednimustine、Procarbazine、Raltitrexed、Ranimustine, Rubitecan, Sapacitabine, Semustine, Sitimagene ceradenovec, Strataplatin, Streptozocin, Talaporfin, Tegafur uracil, Temoporfin, Temozolomide, Teniposide, Tesetaxel, Testolactone, Tetranitrate, Thiotepa, Tiazofurine, Tioguanine, Tipifarnib, Topotecan, Trabectedin, Triaziquone, Triethylenemelamine, Triplatin, Tretinoin, Treosulfan, Trofosfamide, Uramustine, Valrubicin, Verteporfin, Vinblastine, Vincristine, Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zorubicin, and other cytostatic or cytotoxic agents described herein.
[0284] In some embodiments, the additional cancer therapeutic agent is a tyrosine kinase inhibitor, a PI3K / mTOR inhibitor, a PARP inhibitor such as Olaparib, Rucaparib, Niraparib, Talazoparib, Wee1 inhibitors, CDK4 / 6 inhibitors such as Palbociclib, Ribociclib, Abemaciclib, DNA-PK inhibitors, ATM inhibitors, and ATR inhibitors, etc. Any compound of the present invention can be combined with these targeted inhibitors.
[0285] The compounds of the invention and combinations with chemotherapeutic agents or radiation therapy as described above may be administered chronically to maintain a beneficial therapeutic effect or may be administered only short term. Alternatively, they may be administered in a pulsed or continuous manner.
[0286] Other possible additional treatment modalities include gene therapy, peptide and dendritic cell vaccines, synthetic chlorotoxins, and radiolabeled drugs and antibodies.
[0287] Dosage and method of administration
[0288] The dosage of a compound administered to an individual (such as a human) may vary with the specific compound or salt thereof, the method of administration, and the type and stage of the specific disease (such as cancer) being treated. In some embodiments, the amount of the compound or salt thereof is a therapeutically effective amount.
[0289] On the one hand, the effective amount of the compound can be a dosage between about 0.01 and about 100 mg / kg. The effective amount or dosage of the compounds of the present invention can be determined by conventional methods, such as modeling, dose escalation or clinical trials, while considering conventional factors, such as the mode or approach of administration or drug delivery, the pharmacokinetics of the drug, the severity and course of the disease to be treated, the health status, condition and body weight of the subject. Exemplary dosages are in the range of about 0.7 mg to 7 g per day, or about 7 mg to 350 mg per day, or about 350 mg to 1.75 g per day, or about 1.75 to 7 g per day.
[0290] In one aspect, any of the methods provided herein can include administering to a subject a pharmaceutical composition comprising an effective amount of a compound provided herein or a salt thereof and a pharmaceutically acceptable excipient.
[0291] The compound or composition of the present invention can be given to an individual according to an effective dosing regimen, for a desired time or period, such as at least about 1 month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, in some variants, it is possible to continue the individual life period. In one variant, the compound is administered with a daily or intermittent regimen. The compound can be continuously (for example, at least once a day) administered to an individual over a period of time. The frequency of administration can also be less than once a day, for example, administered approximately once a week. The frequency of administration can be more than once a day, for example, twice or three times a day. The frequency of administration can also be intermittent, including "drug holidays" (for example, once a day administration for 7 days, then no administration for 7 days, repeating any 14-day period, such as about 2 months, about 4 months, about 6 months or longer). Any frequency of administration and any dosage described herein can be used for any compound described herein.
[0292] The compounds or salts thereof provided herein can be administered to individuals via various routes, including, for example, intravenous, intramuscular, subcutaneous, oral and transdermal. The compounds provided herein can be frequently administered at low doses (referred to as "metronomic therapy"), or as part of a maintenance therapy using the compound alone or in combination with one or more other drugs. Metronomic therapy or maintenance therapy may include administering the compounds provided herein in cycles. Metronomic therapy or maintenance therapy may include administering the compounds provided herein intratumorally.
[0293] In one aspect, the invention provides a method of treating cancer in an individual, the method being performed by parenteral administration of an effective amount of a compound or a salt thereof to an individual (e.g., a human). In some embodiments, the route of administration is intravenous, intraarterial, intramuscular, or subcutaneous. In some embodiments, the route of administration is oral. In other embodiments, the route of administration is transdermal.
[0294] The present invention also provides compositions (including pharmaceutical compositions) as described herein for use in treating, preventing and / or delaying the onset and / or development of cancer and other methods described herein. In certain embodiments, the composition comprises a pharmaceutical formulation in unit dosage form.
[0295] Also provided are articles of manufacture comprising the compounds of the present disclosure described herein or salts thereof, compositions and unit doses in suitable packaging for use in the methods described herein. Suitable packaging is known in the art and includes, for example, vials, containers, ampoules, bottles, jars, flexible packaging, etc. The articles of manufacture may further be sterilized and / or sealed.
[0296] Reagent test kit
[0297] The present disclosure further provides a kit for implementing the method of the present invention, comprising one or more compounds described herein or a composition comprising a compound described herein. The kit can use any compound disclosed herein. In one variation, the kit uses a compound described herein or a pharmaceutically acceptable salt thereof. The kit can be used for any one or more uses described herein, and thus can include instructions for treating cancer.
[0298] The kit generally includes suitable packaging. The kit may include one or more containers comprising any compound described herein. Where cross-reactivity and shelf life permit, each component (if there are multiple components) may be packaged in a separate container, or some components may be combined in one container.
[0299] The kit can be in unit dosage form, bulk packaging (e.g., multi-dose packaging), or subunit dosage. For example, a kit containing a sufficient dose of a compound as disclosed herein and / or a second pharmaceutically active compound that can be used for a disease described in detail herein can be provided to provide effective treatment of an individual over an extended period of time (such as 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months or any time longer). The kit can also include multiple unit doses of the compound and instructions for use, and is packaged in an amount sufficient for storage and use in a pharmacy (e.g., a hospital pharmacy and a compounding pharmacy).
[0300] The kit may optionally include a set of instructions, usually written instructions, although electronic storage media (e.g., magnetic or optical disks) containing instructions are also acceptable, which instructions relate to the use of the components of the invention. The instructions accompanying the kit typically include information about the components and their administration to an individual.
[0301] The present invention may be further understood by reference to the following examples, which are provided by way of illustration and are not meant to be limiting.
[0302] Example
[0303] Example-1: Synthesis of 5-(6-phenyl-5-((piperidin-4-ylmethyl)amino)pyridazin-3-yl)amino)pyrazine-2-carbonitrile (Compound No. 1.1)
[0304]
[0305] Step-1: Synthesis of tert-butyl 4-(((3,6-dichloropyridazin-4-yl)amino)methyl)piperidine-1-carboxylate: 3,4,6-trichloropyridazine (0.500 g, 2.74 mmol, 1.0 eq.) and tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (0.645 g, 3.02 mmol, 1.10 eq.) were dissolved in THF and heated at 100 °C overnight. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography (0-30% ethyl acetate in hexane as eluent) to give tert-butyl 4-(((3,6-dichloropyridazin-4-yl)amino)methyl)piperidine-1-carboxylate (0.250 g, 26% yield) as a yellow solid. LCMS: 361.2 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ7.30(t,J=5.5Hz,1H),7.05(s,1H),3.92(d,J=11.4Hz,2H),3.14(t,J=6.6Hz,2H),2.67(br.s.,2H) ,1.78(br.s.,1H),1.63(d,J=12.3Hz,2H),1.38(s,6H),1.33(br.s.,1H),1.30-1.11(m,4H),1.02(dt,J=8.1,11.9Hz,2H).
[0306] Step-2: Synthesis of tert-butyl 4-(((6-chloro-3-phenylpyridazin-4-yl)amino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-(((3,6-dichloropyridazin-4-yl)amino)methyl)piperidine-1-carboxylate (0.500, 1.38 mmol, 1.0 eq.) obtained in dioxane solution:water (10:4 mL) were added phenylboronic acid (0.186 g, 1.52 mmol, 1.1 eq.), Na2CO3 (0.294 g, 2.77 mmol, 2.0 eq.) followed by Pd(PPh3)Cl2 (0.050 g, 0.069 mmol, 0.05 eq.). The resulting reaction mixture was heated at 100°C overnight. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography (0-30% ethyl acetate in hexanes as eluent) to give the desired product (0.200 g, 35% yield) as a yellow solid. LCMS: 403.3 [M+H] + .
[0307] Step-3: Synthesis of tert-butyl 4-(6-(5-cyanopyrazin-2-yl)amino)-3-phenylpyridazin-4-yl)amino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-phenylpyridazin-4-yl)amino)methyl)piperidine-1-carboxylate (0.100 g, 0.248 mmol, 1.0 eq.) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.036 g, 0.298 mmol, 1.2 eq.), Cs2CO3 (0.122 g, 0.373 mmol, 1.5 eq.), Xanthphos (0.015 g, 0.0248 mmol, 0.1 eq.) and then Pd2(dba)3 (0.012 g, 0.0124 mmol, 0.05 eq.). The resulting reaction mixture was heated at 180 ° C for 1.5 hours in a microwave reactor. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50mL x2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography (0-3% MeOH in DCM as eluent) to obtain the desired product (0.035g, 29% yield) as an off-white solid. LCMS: 487.3 [M + H] + ; 1 H NMR(400MHz,DMSO-d6)δ10.83(br.s.,1H),9.04(br.s.,1H),8.78(s,1H),7.64-7.43(m,4H),7.28(s,2H),6.32(br.s.,1H),3.9 4(br.s.,2H),3.01(d,J=6.1Hz,2H),2.67(br.s.,2H),1.84(br.s.,1H),1.67(d,J=12.3Hz,2H),1.39(s,9H),1.13-0.93(m,2H).
[0308] Step-4: Synthesis of 5-((6-phenyl-5-((piperidin-4-ylmethyl)amino)pyridazin-3-yl)amino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-(((6-((5-cyanopyrazin-2-yl)amino)-3-phenylpyridazin-4-yl)amino)methyl)piperidine-1-carboxylate (0.035 g, 0.072 mmol) in DCM (5 mL) was added TFA (0.3 mL) at room temperature and the resulting reaction mixture was stirred at room temperature overnight. The formation of the product was confirmed by LCMS. The reaction mixture was concentrated under reduced pressure. The residue obtained was washed with n-pentane and then treated with diethyl ether to obtain the desired product in the form of TFA salt (0.30 g, 3% yield) as an off-white solid. LCMS: 387.3 [M+H] + ;1 H NMR(400MHz,DMSO-d6)δ8.94-8.72(m,2H),8.52(br.s.,1H),8.22(br.s.,1H),7.68-7.46(m,3H),7.31(s,1H),7.06(br.s.,1 H), 3.31 (d, J = 12.3Hz, 2H), 3.22-3.03 (m, 2H), 2.92-2.76 (m, 2H), 1.96 (br.s., 1H), 1.85 (d, J = 13.2Hz, 2H), 1.46-1.22 (m, 2H).
[0309] Example 2: Synthesis of 6-((5-cyanopyrazin-2-yl)amino)-4-((morpholin-2-ylmethyl)amino)pyridazine-3-carboxamide (Compound No. 1.2)
[0310]
[0311] Step-1: Synthesis of tert-butyl 2-(6-chloro-3-(methoxycarbonyl)pyridazin-4-yl)amino)methyl)morpholine-4-carboxylate: To a stirred solution of methyl 4,6-dichloropyridazine-3-carboxylate (1.0 g, 5.0 mmol, 1.0 eq.) in THF were added tert-butyl 2-(aminomethyl)morpholine-4-carboxylate (1.07 g, 5.0 mmol, 1.0 eq.) and TEA, and the reaction mixture was heated at 100°C under microwave irradiation for 2 hours. After work-up, the reaction mixture was purified by column chromatography to obtain the desired product (0.6 g, 32%). LCMS: 386 [M+1] + .
[0312] Step-2: Synthesis of tert-butyl 2-(((3-carbamoyl-6-chloropyridazin-4-yl)amino)methyl)morpholine-4-carboxylate: A solution of tert-butyl 2-(((6-chloro-3-(methoxycarbonyl)pyridazin-4-yl)amino)methyl)morpholine-4-carboxylate (0.900 g, 2.32 mmol, 1.0 eq.) in methanolic ammonia (10 mL) was stirred at room temperature for 15 hours. The progress of the reaction was monitored by TLC and LCMS. After completion, the reaction mixture was evaporated under reduced pressure and triturated with DCM:hexane to obtain the desired product (850 mg, 98%). LCMS: 372 [M+1] + .
[0313] Step-3: Synthesis of 6-((5-cyanopyrazin-2-yl)amino)-4-((morpholin-2-ylmethyl)amino)pyridazine-3-carboxamide: To a stirred solution of tert-butyl 2-(((3-carbamoyl-6-chloropyridazin-4-yl)amino)methyl)morpholine-4-carboxylate and 5-aminopyrazine-2-carbonitrile (27 mg, 0.226 mmol, 1.2 eq.) in dioxane (4 mL) was added cesium carbonate (184 mg, 0.565 mmol, 3 eq.) and purged for 10 minutes. Then tris(dibenzylideneacetone)dipalladium(0) (8.62 mg, 0.0094 mmol, 0.05 eq.) and Xanthphos (10.91 mg, 0.0188 mmol, 0.1 eq.) were added and purged for another 15 minutes. Then the reaction mixture was heated at 180 °C for 45 minutes using microwave irradiation. The reaction mixture was extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with water (20 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product, which was further dissolved in dioxane (5 mL), a solution of hydrochloric acid in dioxane (0.5 mL) was added dropwise and the reaction mixture was stirred at room temperature until precipitation occurred, filtered, washed with ether (15 mL) and n-pentane (15 mL), and dried to obtain a crude product, which was purified by reverse phase column chromatography to obtain the desired product (5 mg, 7%). LCMS: 356 [M+1] + . 1 H NMR (400MHz, DMSO-d6) δ11.08(br.s.,2H),8.92-9.03(m,2H),8.82(d,J=1. 32Hz,1H),8.38(br.s.,1H),7.64(br.s.,1H),7.46(s,1H),4.09(d,J=4.82 Hz,1H),3.95(d,J=8.77Hz,1H),3.83(br.s.,1H),3.60-3.71(m,1H),3.12- 3.21 (m, 2H), 3.05 (d, J = 11.84Hz, 2H), 2.83-2.96 (m, 1H), 2.70-2.80 (m, 2H).
[0314] Example 3: Synthesis of 6-((5-cyanopyrazin-2-yl)amino)-4-((piperidin-4-ylmethyl)amino)pyridazine-3-carboxamide (Compound No. 1.3)
[0315]
[0316] Step-1: Synthesis of methyl 4-(((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)amino)-6-chloropyridazine-3-carboxylate: To a stirred solution of methyl 4,6-dichloropyridazine-3-carboxylate (1.0 g, 5.0 mmol, 1.0 eq.) in THF were added tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (1.06 g, 5.0 mmol, 1.0 eq.) and TEA, and the reaction mixture was heated at 100° C. under microwave irradiation for 2 hours. After work-up, the reaction mixture was purified by column chromatography to obtain the desired product (0.650 g, 35%). LCMS: 384 [M+1] + .
[0317] Step-2: Synthesis of tert-butyl 4-(((3-carbamoyl-6-chloropyridazin-4-yl)amino)methyl)piperidine-1-carboxylate: A solution of tert-butyl 2-(((6-chloro-3-(methoxycarbonyl)pyridazin-4-yl)amino)methyl)morpholine-4-carboxylate (0.200 g, 2.32 mmol, 1.0 eq.) in methanolic ammonia (5 mL) was stirred at room temperature for 15 hours. The progress of the reaction was monitored by TLC and LCMS. After completion, the reaction mixture was evaporated under reduced pressure and triturated with DCM:hexane to obtain the desired product (180 mg, 94%). LCMS: 370 [M+1] + .
[0318] Step-3: Synthesis of 6-((5-cyanopyrazin-2-yl)amino)-4-((piperidin-4-ylmethyl)amino)pyridazine-3-carboxamide: To tert-butyl 4-(((3-carbamoyl-6-chloropyridazin-4-yl)amino)methyl)piperidine-1-carboxylate (100 mg, 0.271 mmol, 1 eq.) and 5-aminopyrazine-2-carbonitrile (39.02 mg, 0.3252 mmol), 1.2 eq.) of dioxane (6 In a 5% flask (10 mL) solution of 1% pyrrolidone (20 mL) and 1% pyrrolidone (40 mL) of 1% pyrrolidone (50 mL) of 1% pyrrolidone (60 mL) of 1% pyrrolidone (70 mL) of 1% pyrrolidone (80 mL) of 1% pyrrolidone (100 mL) of 1% pyrrolidone (60 mL) of 1% pyrrolidone (70 mL) of 1% pyrrolidone (80 mL) of 1% pyrrolidone (70 mL) of 1% pyrrolidone (80 mL) of 1% pyrrolidone (60 mL) of 1% pyrrolidone (70 mL) of 1% pyrrolidone (8 ... LCMS: 354[M+1]+ . 1 HNMR(400MHz,DMSO-d6)δ8.92-9.04(m,2H),8.83(s,1H),8.37(br.s.,1H),7.64(br.s.,1H),7.44(s,1H), 2.97-3.16(m,4H),2.56-2.72(m,2H),2.33(br.s.,1H),1.73(d,J=13.59Hz,2H),1.26(d,J=10.52Hz,2H).
[0319] Example-4: N 3 -(1-methyl-1H-pyrazol-4-yl)-N 5 Synthesis of -(morpholin-2-ylmethyl)-6-phenylpyridazine-3,5-diamine (Compound No. 1.4)
[0320]
[0321] Step-1: Synthesis of tert-butyl 2-(((3,6-dichloropyridazin-4-yl)amino)methyl)morpholine-4-carboxylate: 3,4,6-trichloropyridazine (0.50 g, 2.74 mmol, 1.0 eq.) and tert-butyl 2-(aminomethyl)morpholine-4-carboxylate (0.65 g, 3.02 mmol, 1.10 eq.) were dissolved in THF (10 mL) and heated at 100 °C overnight. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography (0-30% ethyl acetate in hexane as eluent) to obtain the desired product (0.25 g, 25%) as a yellow solid. LCMS: 363 [M+H] + .
[0322] Step-2: tert-Butyl 2-(((6-chloro-3-phenylpyridazin-4-yl)amino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-(((3,6-dichloropyridazin-4-yl)amino)methyl)morpholine-4-carboxylate (0.200, 0.552 mmol, 1.0 eq.) in dioxane / water (5:2 mL) was added phenylboronic acid (0.075 g, 0.607 mmol, 1.1 eq.), Na2CO3 (0.118 g, 1.104 mmol, 2.0 eq.) followed by Pd(PPh3)Cl2 (0.020 g, 0.027 mmol, 0.05 eq.). The resulting reaction mixture was heated at 100°C overnight. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mLx2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography (10-30% ethyl acetate in hexanes as eluent) to give the desired product (0.12 g, 54%) as a yellow solid. LCMS: 405 [M+H] + .
[0323] Step-3: Synthesis of tert-butyl 2-((((6-((1-methyl-1H-pyrazol-4-yl)amino)-3-phenylpyridazin-4-yl)amino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-(((6-chloro-3-phenylpyridazin-4-yl)amino)methyl)morpholine-4-carboxylate (0.100 g, 0.247 mmol, 1.0 eq.) in dioxane (3 mL) was added 1-methyl-1H-pyrazol-4-amine (0.027 g, 0.272 mmol, 1.0 eq.) under nitrogen atmosphere. l, 1.2eq.), Cs2CO3 (0.160g, 0.495mmol, 2.0eq.), Xanthphos (0.015g, 0.0248mmol, 0.1eq.), followed by the addition of Pd2(dba)3 (0.023g, 0.024mmol, 0.10eq.). The resulting reaction mixture was heated in a microwave reactor at 140°C for 1 hour. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography (0-30% ethyl acetate in hexane as eluent) to obtain the desired product (0.050g, 40%) as an off-white solid. LCMS: 466[M+H] +
[0324] Step-4: N 3 -(1-methyl-1H-pyrazol-4-yl)-N 5Synthesis of -(morpholin-2-ylmethyl)-6-phenylpyridazine-3,5-diamine: tert-Butyl 2-(((6-((1-methyl-1H-pyrazol-4-yl)amino)-3-phenylpyridazin-4-yl)amino)methyl)morpholine-4-carboxylate (0.050 g, 0.107 mmol) was dissolved in 4N dioxane (5 mL) and the resulting reaction mixture was stirred at room temperature overnight. The product formation was confirmed by LCMS. The reaction mixture was concentrated under reduced pressure. The crude product obtained was purified by reverse phase HPLC to obtain the desired product (0.005 g, 12%) as a brown semi-solid. LCMS: 366 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ8.65(br.s.,1H),7.95(s,1H),7.64-7.35(m,5H),6.03(s,1H),5.51(br.s.,1H),3.80(s,4H ), 3.48-3.33 (m, 4H), 3.06 (dd, J = 6.1, 14.0Hz, 3H), 2.79 (d, J = 11.4Hz, 1H), 2.72-2.57 (m, 2H), 2.39 (d, J = 10.1Hz, 1H).
[0325] Example 5: Synthesis of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (Compound No. 1.5)
[0326]
[0327] Step-1: Synthesis of 4-((4-(tert-butoxycarbonyl)morpholin-2-yl)methylamino)-6-chloropyridazine-3-carboxylic acid: tert-Butyl 2-((6-chloro-3-(methoxycarbonyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.192 g, 0.5 mmol, 1.0 eq.) was dissolved in THF (2 mL). To the solution was added 2 mL of aqueous lithium hydroxide (0.052 g, 1.0 mmol, 2.0 eq.) solution and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo and the reaction mixture was acidified with dilute HCl to obtain a precipitate, which was filtered and dried in vacuo to obtain the title compound (0.090 g, 48%). LCMS: 371 [M+H] + .
[0328] Step-2: Synthesis of tert-butyl 2-((6-chloro-3-iodopyridazin-4-ylamino)methyl)morpholine-4-carboxylate: A 10 mL microwave vial was loaded with I2 (0.101 g, 4.0 eq, 0.4 mmol), followed by anhydrous K3PO4 (0.021 g, 0.1 mmol, 1.0 eq.), 4-((4-(tert-butoxycarbonyl)morpholin-2-yl)methylamino)-6-chloropyridazine-3-carboxylic acid (0.037 g, 0.1 mmol, 1.0 eq.) and acetonitrile (1.5 mL). The reaction mixture was heated at 100 ° C for 1 hour using microwave radiation; the reaction mixture was cooled to room temperature and diluted with saturated aqueous sodium thiosulfate solution (2 mL). The reaction mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed (brine), dried (anhydrous Na2SO4), and concentrated under reduced pressure to give the title compound (0.025 g, 55%), which was used in the next step without further purification. LCMS: 453 [M+H] + .
[0329] Step-3: Synthesis of tert-butyl 2-((6-chloro-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a stirred solution of tert-butyl 2-((6-chloro-3-iodopyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.022 g, 0.05 mmol, 1.0 eq.) in DMF (1 mL) was added (1,10-phenanthroline)(trifluoromethyl)copper(I) (0.019 g, 0.06 mmol, 1.2 eq.). The reaction mixture was purged with N2 and heated at 80°C for 18 hours. After completion, water was added and the reaction mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed (brine), dried (anhydrous Na2SO4) and concentrated under reduced pressure to obtain the title compound (0.010 g, 52%). LCMS: 397 [M+H] + .
[0330] Step-4: Synthesis of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-((6-chloro-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.270 g, 0.681 mmol, 1.0 eq.) in dioxane (5 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.081 g, 0.681 mmol, 1.0 eq.), Cs2CO3 (0.442 g, 1.36 mmol, 2.0 eq.), X-phos (0.031 g, 0.034 mmol, 0.05 eq.) followed by the addition of Pd2(dba)3 (0.016 g, 0.034 mmol, 0.0.05 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 1 hour. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography followed by RP-HPLC to obtain the title compound product (0.020 g, 6%). LCMS: 481 [M+H] +1 HNMR(400MHz,DMSO-d6)δ11.20(br.s.,1H),8.89(br.s.,1H),8.83(br.s.,1H),7.68(s,1H),6.94(br.s.,1 H), 3.84 (d, J = 11.40Hz, 2H), 3.69 (d, J = 14.47Hz, 1H), 3.60 (br.s., 1H), 3.38 (br.s., 1H), 2.90 (br.s., 2H).
[0331] Example 6: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (Compound No. 1.6)
[0332]
[0333] Step-1: Synthesis of 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methylamino)-6-chloropyridazine-3-carboxylic acid: Methyl 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methylamino)-6-chloropyridazine-3-carboxylate (0.90 g, 2.34 mmol, 1.0 eq.) was dissolved in MeOH (5 mL). To the solution was added aqueous sodium hydroxide solution (0.28 g, 7.02 mmol, 3.0 eq.) and the reaction mixture was stirred for 2 hours. The reaction mixture was concentrated in vacuo and the reaction mixture was acidified with dilute citric acid to obtain a precipitate, which was filtered and dried in vacuo to obtain the title compound (0.6 g, 69%). LCMS: 371.3 [M+H] + .
[0334] Step-2: Synthesis of tert-butyl 4-((6-chloro-3-iodopyridazin-4-ylamino)methyl)piperidine-1-carboxylate: A 30 mL microwave vial was charged with I2 (1.648 g, 4.0 eq, 6.48 mmol), followed by anhydrous K3PO4 (0.343 g, 1.62 mmol, 1.0 eq.), 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methylamino)-6-chloropyridazine-3-carboxylic acid (0.6 g, 1.621 mmol, 1.0 eq.) and acetonitrile (10 mL). The reaction was heated at 100 °C for 1 hour using microwave irradiation; the reaction mixture was cooled to room temperature and diluted with saturated aqueous sodium thiosulfate solution (5 mL). The reaction mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed (brine), dried (anhydrous Na2SO4) and concentrated under reduced pressure to give the title compound (0.5 g, 68%), which was used in the next step without further purification. LCMS: 453.2 [M+H] + .
[0335] Step-3: tert-Butyl 4-((6-chloro-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a stirred solution of tert-butyl 4-((6-chloro-3-iodopyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.5 g, 1.10 mmol, 1.0 eq.) in DMF (3 mL) was added (1,10-phenanthroline)(trifluoromethyl)copper(I) (0.44 g, 1.32 mmol, 1.2 eq.). The reaction mixture was purged with N2 and heated at 80°C for 18 hours. After completion, water was added and the reaction mixture was extracted with ethyl acetate (3×10 mL). The combined organic layers were washed (brine), dried (anhydrous Na2SO4) and concentrated under reduced pressure to afford the title compound (0.3 g, 69%). LCMS: 395.3[M+H] + .
[0336] Step-4: tert-Butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.3 g, 0.76 mmol, 1.0 eq.) in dioxane (5 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.091 g, 0.76 mmol, 1.0 eq.), Cs2CO3 (0.494 g, 1.52 mmol, 2.0 eq.), X-phos (0.018 g, 0.038 mmol, 0.05 eq.) followed by the addition of Pd2(dba)3 (0.034 g, 0.038 mmol, 0.0.05 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 1 hour. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography followed by RP-HPLC to obtain the title compound product (0.020 g, 6%). LCMS: 481 [M+H] +1 HNMR(400MHz,DMSO-d6)δd 8.56(br.s.,2H),7.38(br.s.,1H),6.71(s,2H),3.91(br.s.,2H),3.08( d,J=6.14Hz,2H),1.82(br.s.,1H),1.54-1.70(m,3H),0.92-1.12(m,2H).
[0337] Example-7: Synthesis of 2-((6-(5-cyanopyrazin-2-ylamino)-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)morpholin-4-ium 2,2,2-trifluoroacetate (Compound No. 1.7)
[0338]
[0339] To a solution of tert-butyl 2-((6-chloro-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.010 g, 0.02 mmol) in DCM (3 mL) was added TFA (0.1 mL) at room temperature and the resulting reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS and TLC. Diethyl ether was added to the reaction mixture to obtain a precipitate. The solvent was decanted and the solid was dried in vacuo to obtain the title compound (0.003 g, 39%). LCMS: 381.4 [M+H] + ; 1H NMR(400MHz,DMSO-d6)δ11.28(s,1H),8.96(br.s.,1H),8.87(d,J=6.58Hz,2H) ,7.66-7.75(m,1H),6.96(d,J=5.70Hz,1H),4.01(d,J=10.09Hz,1H),3.92(d,J =8.77Hz,1H),3.64-3.74(m,1H),3.39(d,J=5.70Hz,2H),3.27(d,J=12.72Hz,1 H), 3.19 (d, J = 12.28Hz, 1H), 3.02 (d, J = 10.96Hz, 1H), 2.85 (d, J = 10.96Hz, 1H).
[0340] Example 8: Synthesis of 4-((6-(5-cyanopyrazin-2-ylamino)-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)piperidinium 2,2,2-trifluoroacetate (Compound No. 1.8)
[0341]
[0342] To a solution of tert-butyl 4-((6-chloro-3-(trifluoromethyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.015 g, 0.03 mmol) in DCM (3 mL) was added TFA (0.1 mL) at room temperature and the resulting reaction mixture was stirred at room temperature for 1 hour. Product formation was confirmed by LCMS and TLC. Diethyl ether was added to the reaction mixture to obtain a precipitate. The solvent was decanted and the solid was dried in vacuo to obtain the title compound (0.007 g, 61%). LCMS: 379.4 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.27(br.s.,1H),8.82-8.94(m,2H),8.75(br.s.,1H),8.59(br.s.,1H),7.68(s,1H),7.11(br.s.,1H),3.28(d,J=12.28Hz,2 H),3.16(br.s.,2H),2.82(d,J=8.33Hz,2H),1.95(br.s.,1H),1.82(d,J=1 2.72Hz,2H),1.32-1.53(m,3H),1.23(br.s.,1H),1.06(d,J=14.03Hz,1H).
[0343] Example-9: Synthesis of 5-(5-(morpholin-2-ylmethoxy)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.9)
[0344]
[0345] Step-1: Synthesis of tert-butyl 2-((6-chloropyridazin-4-yloxy)methyl)morpholine-4-carboxylate: tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (0.733 g, 0.0033 mol, 1.0 eq.) was dissolved in DMSO (10 mL). To the solution was added potassium tert-butoxide (0.380 g, 0.0033 mmol, 1.0 eq.) solution and the reaction mixture was stirred at room temperature for 20 minutes. The reaction mixture was cooled to 0°C and 3,5-dichloropyridazine (0.5 g, 0.0033 mol, 1.0 eq.) was added thereto and the reaction mixture was stirred at room temperature for 16 hours. The reactant was diluted with water and extracted with ethyl acetate. The combined organic layers were washed (brine), dried (anhydrous Na2SO4), and concentrated in vacuo to obtain the title compound (0.800 g, 74%). LCMS: 330 [M+H] + .
[0346] Step-2: Synthesis of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)pyridazin-4-yloxy)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-((6-chloropyridazin-4-yloxy)methyl)morpholine-4-carboxylate (0.2 g, 0.6 mmol, 1.0 eq.) in dioxane (5 mL) was added 5-aminopyrazine-2-carbonitrile (0.072 g, 0.6 mmol, 1.0 eq.), Cs2CO3 (0.395 g, 1.2 mmol, 2.0 eq.), Xantphos (0.017 g, 0.038 mmol, 0.05 eq.) followed by Pd2(dba)3 (0.027 g, 0.038 mmol, 0.05 eq.) under nitrogen atmosphere. The resulting reaction mixture was heated in a microwave reactor at 180°C for 2 hours. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography to give the title compound (0.030 g, 12%). LCMS: 414 [M+H] +
[0347] Step-3: Synthesis of 5-(5-(morpholin-2-ylmethoxy)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)pyridazin-4-yloxy)methyl)morpholine-4-carboxylate (0.030 g, 0.07 mmol) in DCM (5 mL) was added TFA (0.01 mL) at room temperature and the resulting reaction mixture was stirred at room temperature for 15 min. The formation of the product was confirmed by LCMS and TLC. Diethyl ether was added to the reaction mixture to obtain a precipitate. The solvent was decanted and the solid was dried in vacuo to obtain the title compound (0.01 g, 45%). LCMS: 314 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ11.24(br.s.,1H),9.11(br.s.,2H),8.95(br.s.,1H),8.81(br.s.,2H),7.73(br.s.,1H),4.28(br.s.,2H ), 4.10 (br.s., 1H), 4.03 (d, J = 10.96Hz, 1H), 3.77 ( br.s., 1H), 3.36 ( d, J = 10.52Hz, 1H), 3.24 ( d, J = 9.65Hz, 1H), 3.03 ( br.s., 2H).
[0348] Example-10: Synthesis of 5-(5-((1-methylpiperidin-4-yl)methylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.10)
[0349]
[0350] Step-1: Synthesis of 6-chloro-N-((1-methylpiperidin-4-yl)methyl)pyridazin-4-amine: To a solution of 3,5-dichloropyridazine (0.500 g, 0.0033 mol, 1.0 eq.) and (1-methylpiperidin-4-yl)methanamine (0.432 g, 0.0033 mol, 1.0 eq.) in ACN (10 mL) was added DIPEA (1.2 mL, 0.0066 mol, 2.0 eq.). The reaction mixture was heated at 80° C. for 3 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to give a crude product, which was purified by normal phase silica gel column chromatography to give the title compound (0.500 g, 63%). LCMS: 241 [M+H] + .
[0351] Step-2: Synthesis of 5-(5-((1-methylpiperidin-4-yl)methylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of 6-chloro-N-((1-methylpiperidin-4-yl)methyl)pyridazin-4-amine (0.1 g, 0.41 mmol, 1.0 eq.) in DMF (4 mL) was added 5-aminopyrazine-2-carbonitrile (0.055 g, 0.45 mmol, 1.1 eq.), Cs2CO3 (0.4 g, 1.23 mmol, 3.0 eq.), Xantphos (0.023 g, 0.04 mmol, 0.1 eq.) followed by Pd2(dba)3 (0.018 g, 0.02 mmol, 005 eq.) under nitrogen atmosphere. The resulting reaction mixture was heated in a microwave reactor at 180°C for 1 hour. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by RP-HPLC to give the title compound (0.005 g, 4%). LCMS: 325 [M+H] +1 H NMR(400MHz,DMSO-d6)δ8.96(br.s.,1H),8.73(br.s.,1H),8.34(br.s.,1H),7.26(br.s.,1H),7.06(br.s.,1H), 2.98(br.s.,2H),2.86(br.s.,2H),2.21(br.s.,2H),1.90(br.s.,3H),1.71(d,J=10.52Hz,2H),1.23(br.s.,2H).
[0352] Example-11: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide (Compound No. 1.11)
[0353]
[0354] Step-1: Synthesis of tert-butyl 2-((6-chloro-3-(methylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a methanol solution of tert-butyl 2-((6-chloro-3-(methoxycarbonyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.200 g, 0.51 mmol, 1.0 eq.) were added K2CO3 (0.140 g, 1.05 mmol, 2.0 eq.) and methylamine hydrochloride (0.068 g, 1.02 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 24 hours and poured onto ice to obtain a precipitate, which was vacuum filtered to obtain the title compound (0.175 g, 63%). LCMS: 386 [M+H] + .
[0355] Step-2: Synthesis of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(methylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-((6-chloro-3-(methylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.17 g, 0.44 mmol, 1.0 eq.) in dioxane (4 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.058 g, 0.48 mmol, 1.1 eq.), Cs2CO3 (0.43 g, 1.32 mmol, 3.0 eq.), Xantphos (0.025 g, 0.044 mmol, 0.1 eq.) and then Pd2(dba)3 (0.020 g, 0.022 mmol, 0.05 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 1 hour. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column chromatography to obtain the title compound (0.080 g, 39%). LCMS: 470 [M + H] + .
[0356] Step-3: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide: To a solution of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(methylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate in DCM (5 mL) was added TFA (0.26 mL) at room temperature and the resulting reaction mixture was stirred at room temperature for 15 minutes. The formation of the product was confirmed by LCMS and TLC. Diethyl ether was added to the reaction mixture to obtain a precipitate. The solvent was decanted and the solid was dried under vacuum to obtain the title compound (0.05 g, 79%). LCMS: 370 [M+H]+ ; 1 HNMR(400MHz,DMSO-d6)δ11.11(br.s.,1H),8.97-9.08(m,2H),8.86-8.95(m, 2H),8.81(s,1H),7.50(s,1H),4.05(d,J=9.65Hz,1H),3.91(br.s.,1H),3.68 -3.76(m,2H),3.43(d,J=13.59Hz,2H),3.33(d,J=11.84Hz,2H),3.22(d,J=11 .84Hz, 1H), 3.03 (br.s., 1H), 2.89 (d, J = 11.40Hz, 1H), 2.80 (d, J = 4.82Hz, 2H).
[0357] Example-12: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-cyclopropyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide (Compound No. 1.12)
[0358]
[0359] Step-1: Synthesis of tert-butyl 2-((6-chloro-3-(cyclopropylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-((6-chloro-3-(methoxycarbonyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.205 g, 0.53 mol, 1.0 eq.) in methanol were added K2CO3 (0.146 g, 1.06 mmol, 2.0 eq.) and cyclopropylamine (0.060 g, 1.06 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 24 hours and then poured onto ice to obtain a precipitate, which was vacuum filtered to obtain the title compound (0.052 g, 24%). LCMS: 412 [M+H] + .
[0360] Step-2: Synthesis of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(cyclopropylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate: Under nitrogen atmosphere, tert-butyl 2-((6-chloro-3-(cyclopropylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.05 g, 0.12 mmol, 1.0 eq.) was dissolved in dioxane (3 mL). 5-aminopyrazine-2-carbonitrile (0.016 g, 0.13 mmol, 1.1 eq.), Cs2CO3 (0.117 g, 0.36 mmol, 3.0 eq.), Xantphos (0.005 g, 0.008 mmol, 0.05 eq.) were added to the solution, followed by Pd2(dba)3 (0.003 g, 0.003 mmol, 0.002 eq.). The resulting reaction mixture was heated at 180 ° C for 1 hour in a microwave reactor. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase chromatography to obtain the title compound (0.032 g, 53%). LCMS: 496 [M + H] + .
[0361] Step-3: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-cyclopropyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide: To a solution of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(cyclopropylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.030 g, 0.006 mmol) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added and the resulting precipitate was filtered and washed with diethyl ether to obtain the title compound as a TFA salt (0.023 g, 98% yield). LCMS: 396 [M+H] + ; 1 HNMR(400MHz,DMSO-d6)δ11.09(s,1H),8.97-9.03(m,2H),8.95(s,1H),8.89(br.s.,1H),8.82(s,1H),7.47(s ,1H),3.72(br.s.,2H),3.33(d,J=12.28Hz,3H),3.22(d,J=11.84Hz,2H),2.88(br.s.,2H),0.66-0.72(m,4H).
[0362] Example-13: Synthesis of 5-(6-(1-methyl-1H-pyrazol-3-yl)-5-(morpholin-2-ylmethoxy)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.13)
[0363]
[0364] Step-1: Synthesis of tert-butyl 2-((3,6-dichloropyridazin-4-yloxy)methyl)morpholine-4-carboxylate: tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (1.0 g, 0.005 mol, 1.0 eq.) was dissolved in DMSO (10 mL). To the solution was added potassium tert-butoxide (0.613 g, 0.005 mmol, 1.0 eq.) solution and the reaction mixture was stirred at room temperature for 20 minutes. The reaction mixture was cooled to 0°C and 3,4,6-trichloropyridazine (1.0 g, 0.005 mol, 1.0 eq.) was added thereto and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed (brine), dried (anhydrous Na2SO4), and concentrated in vacuo to obtain the title compound (1.0 g, 55%). LCMS: 364 [M+H] + .
[0365] Step-2: Synthesis of tert-butyl 2-((6-chloro-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-yloxy)methyl)morpholine-4-carboxylate: To a stirred solution of tert-butyl 2-((3,6-dichloropyridazin-4-yloxy)methyl)morpholine-4-carboxylate in DMF:water (10 mL; 5 mL) was added 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.14 g, 0.66 mmol, 0.8 eq.). The reaction mixture was purged with nitrogen for 5 minutes followed by loading of K3PO4 (0.521 g, 2.46 mmol, 3.0 eq.) and Pd(dppf)Cl2DCM complex (27 mg, 5 mol%). The reaction mixture was purged with nitrogen again. The reaction mixture was heated at 80°C for 1 hour using microwave irradiation. After completion, the reaction was diluted with water and extracted with ethyl acetate. The combined organic layers (brine) were washed, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography to afford the title compound (0.1 g, 30%). LCMS: 410 [M+1] + .
[0366] Step-3: Synthesis of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-yloxy)methyl)morpholine-4-carboxylate: Under nitrogen atmosphere, tert-butyl 2-((6-chloro-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-yloxy)methyl)morpholine-4-carboxylate (0.2 g, 0.48 mmol, 1.0 eq.) was added to dioxane. 5-aminopyrazine-2-carbonitrile (0.058 g, 0.48 mmol, 1.0 eq.), Cs2CO3 (0.476 g, 1.46 mmol, 3.0 eq.), Xantphos (0.015 g, 0.002 mmol, 0.05 eq.) were added to the (5 mL) solution, followed by Pd2(dba)3 (0.022 g, 0.002 mmol, 0.05 eq.). The resulting reaction mixture was heated at 180 ° C for 1 hour in a microwave reactor. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column chromatography to obtain the title compound (0.1 g, 42%). LCMS: 494 [M+H] + .
[0367] Step-4: Synthesis of 5-(6-(1-methyl-1H-pyrazol-3-yl)-5-(morpholin-2-ylmethoxy)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-yloxy)methyl)morpholine-4-carboxylate (0.1 g, 0.2 mmol, 1.0 eq.) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added and the resulting precipitate was filtered and washed with diethyl ether to obtain the title compound as a TFA salt (4 mg, 5%). LCMS: 394 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.96(s,1H),8.82(s,1H),7.82(d,J=4.82Hz,2H),6.82(s,1H),4.14(d,J=8.33Hz,2H),3.94( s, 2H), 3.78 (d, J = 9.21Hz, 2H), 3.50 (d, J = 10.96Hz, 2H), 2.93 (d, J = 11.84Hz, 1H), 2.68 (br.s., 2H), 1.87 (br.s., 3H).
[0368] Example-14: Synthesis of 5-(6-methyl-5-(morpholin-2-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.14)
[0369]
[0370] Step-1: Synthesis of tert-butyl 2-((3,6-dichloropyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a solution of 3,4,6-trichloropyridazine (0.500 g, 2.7 mmol, 1.0 eq.) and tert-butyl 2-(aminomethyl)morpholine-4-carboxylate (0.590 g, 2.7 mmol, 1.0 eq.) in ACN (5 mL) was added DIPEA (0.95 mL, 5.4 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature overnight and concentrated under vacuum to give a crude product, which was purified by normal phase silica gel column chromatography to give the title compound (0.500 g, 51%). LCMS: 363 [M+H] + .
[0371] Step-2: Synthesis of tert-butyl 2-((6-chloro-3-methylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a stirred solution of tert-butyl 2-((3,6-dichloropyridazin-4-ylamino)methyl)morpholine-4-carboxylate 0.4 g, 1.1 mmol, 1.0 eq.) in toluene / water (5 mL: 0.5 mL) was added methylboric acid (0.19 g, 3.3 mmol, 3.0 eq.). The reaction mixture was purged with nitrogen for 5 minutes followed by loading Cs2CO3 (0.72 g, 2.2 mmol, 2.0 eq.) and Pd(dppf)Cl2 (45 mg, 5 mol%). The reaction mixture was purged with nitrogen again. The reaction mixture was heated at 100°C overnight. After completion, the reaction was diluted with water and extracted with ethyl acetate. The combined organic layer (brine) was washed, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography to give the title compound (0.2 g, 53%). LCMS: 343 [M+H] + .
[0372] Step-3: Synthesis of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-methylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-((6-chloro-3-methylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.22 g, 0.6 mmol, 1.0 eq.) in DMF (5 mL) was added 5-aminopyrazine-2-carbonitrile (0.09 g, 0.77 mmol, 1.2 eq.), Cs2CO3 (0.627 g, 1.9 mmol, 3.0 eq.), Xantphos (0.038 g, 10 mol%) followed by Pd2(dba)3 (0.030 g, 5 mol%) in a nitrogen atmosphere. The resulting reaction mixture was heated in a microwave reactor at 180°C for 90 min. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column chromatography to obtain the title compound (0.03 g, 22%). LCMS: 427 [M+H] + .
[0373] Step-4: Synthesis of 5-(6-methyl-5-(morpholin-2-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-methylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.03 g, 0.07 mmol, 1.0 eq.) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 30 minutes. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added, and the resulting precipitate was filtered and washed with diethyl ether to obtain the title compound as a TFA salt (10 mg, 43%). LCMS: 327 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ9.02(br.s.,1H),8.94(br.s.,1H),8.84(s,1H),8.70(br.s.,1H),7.11(s,1H),3.90-4.04(m,2H),3.62-3.7 4(m,3H),3.41(br.s.,2H),3.34(d,J=12.28Hz,2H),3.21(d,J=12.28Hz,1H),3.02(br.s.,1H),2.90(d,J=11.40Hz,1H),2.43(s,3H).
[0374] Example 15: Synthesis of 5-(6-methyl-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.15)
[0375]
[0376] Step-1: Synthesis of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of 3,4,6-trichloropyridazine (1.0 g, 5.4 mmol, 1.0 eq.) and tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (1.16 g, 5.4 mmol, 1.0 eq.) in ACN (10 mL) was added DIPEA (1.9 mL, 10.0 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature overnight and concentrated in vacuo to give a crude product, which was purified by normal phase silica gel column chromatography to give the title compound (1.5 g, 79%). LCMS: 361 [M+H] + .
[0377] Step-2: Synthesis of tert-butyl 4-((6-chloro-3-methylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a stirred solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.33 g, 0.9 mmol, 1.0 eq.) in toluene / water (4 mL:0.5 mL) was added methylboric acid (0.11 g, 1.8 mmol, 2.0 eq.) and Cs2CO3 (0.59 g, 1.8 mmol, 2.0 eq.). The reaction mixture was purged with nitrogen for 15 minutes and Pd(dppf)Cl2 (36 mg, 5 mol%) was added. The reaction mixture was purged with nitrogen again. The reaction mixture was heated at 100°C for 1 hour using microwave irradiation. After completion, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layer (brine) was washed, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography to give the title compound (0.15 g, 49%). LCMS: 341 [M+H] + .
[0378] Step-3: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-methylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-methylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.15 g, 0.44 mmol, 1.0 eq.) in DMF (5 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.058 g, 0.48 mmol, 1.1 eq.), Cs2CO3 (0.430 g, 1.3 mmol, 3.0 eq.), Xantphos (0.025 g, 10 mol%) followed by Pd2(dba)3 (0.020 g, 5 mol%). The resulting reaction mixture was heated in a microwave reactor at 180°C for 90 min. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column chromatography to obtain the title compound (0.100 g, 53%). LCMS: 425 [M+H] + .
[0379] Step-4: Synthesis of 5-(6-methyl-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-methylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.1 g, 0.23 mmol, 1.0 eq.) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 30 minutes. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added, and the resulting precipitate was filtered and washed with diethyl ether to obtain the title compound as a TFA salt (20 mg, 56%). LCMS: 325 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ8.81(br.s.,2H),8.49(br.s.,1H),8.21(br.s.,1H),7.07(br.s.,1H),3.1 5(br.s.,2H),2.84(d,J=9.65Hz,3H),2.40(br.s.,3H),1.88(d,J=12.28Hz,3H),1.34(br.s.,3H).
[0380] Example 16: Synthesis of 5-(6-(4-fluoro-3-methylphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.16)
[0381]
[0382] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(4-fluoro-3-methylphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.3 g, 0.830 mmol, 1.0 eq.) in dioxane:water (5:05, 5.50 mL) was added sodium carbonate (0.218 g, 2.075 mmol, 2.5 eq.), 4-fluoro-3-methylphenylboronic acid (0.152 g, 0.99 mmol, 1.2 eq.) and Pd(dppf)Cl2.DCM complex (0.027 g, 0.033 g, 0.04 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 100°C for 16 hours. The reaction mixture was diluted with water (50 ml) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography to obtain the title compound (240 mg, 66%), LCMS: 434.19 [M+H] + .
[0383] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-fluoro-3-methylphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(4-fluoro-3-methylphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.236 g, 0.54 mmol, 1.0 eq.) in dioxane (4 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.085 g, 0.70 mmol, 1.3 eq.), Cs2CO3 (0.438 g, 1.35 mmol, 2.5 eq.), X-phos (0.062 g, 0.108 mmol, 0.2 eq.) and then Pd2(dba)3 (0.049 g, 0.54 mmol, 0.1 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 90 minutes. TLC showed new spots formed with the starting material. Product formation was confirmed by LCMS. The reaction mixture was diluted with water (20 ml) and extracted with ethyl acetate (70 mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography followed by RP-HPLC to obtain the title compound (45 mg, 16%). LCMS: 518.2 [M + H] + .
[0384] Step-3: Synthesis of 5-(6-(4-fluoro-3-methylphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-fluoro-3-methylphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.045 g, 0.086 mmol) in DCM (3.0 ml) was added dropwise trifluoroacetic acid (0.4 mL) at 0°C. The resulting reaction mixture was then stirred for 40 minutes. LCMS showed that the desired product was formed. To the reaction mixture was added n-pentane (10 mL) with stirring to obtain a suspension, which was filtered to obtain the title compound (21 mg, 59%). LCMS: 418.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ8.85(br.s.,2H),8.52(br.s.,2H),8.25(br.s.,2H),7.50(d,J=6.58Hz,1H),7.43(br.s.,1H),7.27-7.35(m,2H),3.30(d ,J=11.84Hz,2H),3.09(br.s.,2H),2.84(d,J=10.96Hz,3H),2.32(br.s. ,3H),1.94(br.s.,1H),1.84(d,J=13.59Hz,2H),1.34(d,J=12.28Hz,2H).
[0385] Example-17: Synthesis of 5-(6-cyclopropyl-5-(morpholin-2-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.17)
[0386]
[0387] Step-1: Synthesis of tert-butyl 2-((6-chloro-3-cyclopropylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To stirred tert-butyl 2-((3,6-dichloropyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.4 g, 1.1 mmol, 1.0 eq.) in toluene:water (5 mL; 0.5 mL) were added cyclopropylboronic acid (0.28 g, 3.3 mmol, 3.0 eq.)) and Cs2CO3 (0.72 g, 2.2 mmol, 2.0 eq.). The reaction mixture was purged with nitrogen for 5 minutes and then Pd(dppf)Cl2 (44 mg, 5 mol%) was added. The reaction mixture was purged with nitrogen again. The reaction mixture was heated at 100°C overnight. After completion, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers (brine) were washed, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography to give the title compound (0.23 g, 57%). LCMS: 369 [M+H] + .
[0388] Step-2: Synthesis of tert-butyl 2-((6-(5-cyanopyrazine-2-ylamino)-3-cyclopropylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-((6-chloro-3-cyclopropylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate in dioxane (4 mL) was added 5-aminopyrazine-2-carbonitrile (0.082 g, 0.68 mmol, 1.1 eq.), Cs2CO3 (0.609 g, 1.9 mmol, 3.0 eq.), Xantphos (0.036 g, 10 mol%), followed by Pd2(dba)3 (0.028 g, 5 mol%) under nitrogen atmosphere. The resulting reaction mixture was heated at 180°C for 90 minutes in a microwave reactor. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column chromatography to obtain the title compound (0.1 g, 36%). LCMS: 453 [M+H] + .
[0389] Step-3: Synthesis of 5-(6-cyclopropyl-5-(morpholin-2-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 2-((6-(5-cyanopyrazin-2-ylamino)-3-cyclopropylpyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.1 g, 0.2 mmol, 1.0 eq.) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 30 minutes. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added, and the resulting precipitate was filtered and washed with diethyl ether to obtain the title compound as a TFA salt (7 mg, 10%). LCMS: 353 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ9.02(br.s.,1H),8.71(br.s.,1H),6.97(br.s.,1H),6.79(br.s.,1H),3.75(d,J=10.52Hz,2H),3.60(br.s.,1H),3. 16(br.s.,2H),2.86(d,J=12.28Hz,1H),2.65(br.s.,1H),2.08(d,J=5.70Hz,1H),1.79(br.s.,4H),1.23(br.s.,1H),0.93(d,J=6.58Hz,2H).
[0390] Example 18: Synthesis of 5-(6-cyclopropyl-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.18)
[0391]
[0392] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-cyclopropylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a stirred solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.5 g, 1.3 mmol, 1.0 eq.) in toluene:water (5 mL; 0.5 mL) was added cyclopropylboronic acid (0.35 g, 3.9 mmol, 3.0 eq.) and Cs2CO3 (0.9 g, 2.7 mmol, 2.0 eq.). The reaction mixture was purged with nitrogen for 5 minutes followed by the addition of Pd(dppf)Cl2 (56 mg, 5 mol%). The reaction mixture was purged with nitrogen again. The reaction mixture was heated at 100°C overnight. After completion, the reaction was diluted with water and extracted with ethyl acetate. The combined organic layers (brine) were washed, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase column chromatography to give the title compound (0.200 g, 42%). LCMS: 367 [M+H]+ .
[0393] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-cyclopropylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of butyl 4-((6-chloro-3-cyclopropylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.2 g, 0.54 mmol, 1.0 eq.) in DMF (4 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.078 g, 0.6 mmol, 1.2 eq.), Cs2CO3 (0.53 g, 1.6 mmol, 3.0 eq.), Xantphos (0.031 g, 10 mol%) followed by Pd2(dba)3 (0.024 g, 5 mol%). The resulting reaction mixture was heated in a microwave reactor at 180°C for 1 hour. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase chromatography to obtain the title compound (0.03 g, 12%). LCMS: 451 [M+H] + .
[0394] Step-3: Synthesis of 5-(6-cyclopropyl-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-cyclopropylpyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.03 g, 0.06 mmol, 1.0 eq.) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 30 minutes. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added and the resulting precipitate was filtered and washed with diethyl ether to obtain the title compound as a TFA salt (10 mg, 47%). LCMS: 351 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ10.63(s,1H),8.93(br.s.,1H),8.75(br.s.,1H),8.55(br.s.,1H),7.06(br.s.,1H),6.94(br.s., 1H), 3.10 (br.s., 2H), 2.77-2.92 (m, 2H), 2.06 (br.s., 2H), 1.87 (d, J = 13.59Hz, 3H), 1.40 (d, J = 11.84Hz, 2H), 0.94 (s, 4H).
[0395] Example-19: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-((1-methylpiperidin-4-yl)methylamino)pyridazine-3-carboxamide (Compound No. 1.19)
[0396]
[0397] Step-1: Synthesis of 6-chloro-N-methyl-4-((1-methylpiperidin-4-yl)methylamino)pyridazine-3-carboxamide: To a solution of methyl 4,6-dichloropyridazine-3-carboxylate (0.500 g, 0.0024 mol, 1.0 eq.) and (1-methylpiperidin-4-yl)methanamine (0.310 g, 0.0024 mol, 1.0 eq.) in ACN (10 mL) was added DIPEA (0.83 mL, 0.0048 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo to obtain a crude product, which was purified by normal phase silica gel column chromatography to obtain the title compound (0.800 g, 63%). LCMS: 299 [M+H] + .
[0398] Step-2: Synthesis of 6-chloro-N-methyl-4-((1-methylpiperidin-4-yl)methylamino)pyridazine-3-carboxamide: To a solution of 6-chloro-N-methyl-4-((1-methylpiperidin-4-yl)methylamino)pyridazine-3-carboxamide (0.400 g, 0.0013 mol, 1.0 eq.) in methanol (20 mL) were added K2CO3 (0.55 g, 0.004 mol, 3.0 eq.) and methylamine hydrochloride (0.181 g, 0.0026 mol, 2.0 eq.). The reaction mixture was stirred at room temperature for 24 hours and concentrated under vacuum to obtain a solid, which was added with water (10 mL) and extracted using DCM (20 x 3 mL). The combined organic layers were concentrated to obtain the title compound (0.2 g, 63%). LCMS: 298 [M+H] + .
[0399] Step-3: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-((1-methylpiperidin-4-yl)methylamino)pyridazine-3-carboxamide: To a solution of 6-chloro-N-methyl-4-((1-methylpiperidin-4-yl)methylamino)pyridazine-3-carboxamide (0.1 g, 0.3 mmol, 1.0 eq.) in DMF (4 mL) was added 5-aminopyrazine-2-carbonitrile (0.048 g, 0.4 mmol, 1.2 eq.), Cs2CO3 (0.32 g, 1.0 mmol, 3.0 eq.), Xantphos (0.019 g, 0.03 mmol, 0.1 eq.) and then Pd2(dba)3 (0.015 g, 0.016 mmol, 0.05 eq.) under nitrogen atmosphere. The resulting reaction mixture was heated in a microwave reactor at 180°C for 1 hour. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC to obtain the title compound (0.096 g, 84%). LCMS: 382 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.87(d,J=4.39Hz,2H),8.61(br.s.,1H),8.32(br.s.,1H),8.18(br.s.,1H),7.03(s,1H),3.01(t,J= 6.14Hz,2H),2.70-2.82(m,5H),2.13(s,3H),1.75-1.88(m,2H),1.65(d,J=12.28Hz,2H),1.53(br.s.,1H),1.17-1.33(m,2H).
[0400] Example-20: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-4-(1-methylpiperidin-4-ylamino)pyridazine-3-carboxamide (Compound No. 1.20)
[0401]
[0402] Step-1: Synthesis of 6-chloro-4-(1-methylpiperidin-4-ylamino)pyridazine-3-carboxylic acid methyl ester: To a solution of 4,6-dichloropyridazine-3-carboxylic acid methyl ester (0.5 g, 0.0024 mol, 1.0 eq.) and (1-methylpiperidin-4-yl)methylamine (0.275 g, 0.0024 mol, 1.0 eq.) in ACN (10 mL) was added DIPEA (0.8 mL, 0.0048 mmol, 2.0 eq.). The reaction mixture was stirred and reacted for 16 hours. After the addition of the raw materials, the reaction mixture was concentrated in vacuo to obtain a crude product, which was purified by normal phase silica gel column chromatography to obtain the title compound (0.500 g, 73%). LCMS: 285 [M+H] + .
[0403] Step-2: Synthesis of 6-chloro-4-(1-methylpiperidin-4-ylamino)pyridazine-3-carboxamide: To a solution of methyl 6-chloro-4-(1-methylpiperidin-4-ylamino)pyridazine-3-carboxylate (0.5 g, 0.0016 mol, 1.0 eq.) was added methanolic ammonia (5 mL) at room temperature. The reaction mixture was stirred for 16 hours. After the addition of the raw material, the obtained solid was filtered and dried to obtain the title compound (0.3 g, 69%). LCMS: 270 [M+H] + .
[0404] Step-3: Synthesis of 6-(5-cyanopyrazine-2-ylamino)-4-(1-methylpiperidin-4-ylamino)pyridazine-3-carboxamide: To a solution of 6-chloro-4-(1-methylpiperidin-4-ylamino)pyridazine-3-carboxamide (0.3 g, 1.11 mmol, 1.0 eq.) in dioxane (5 mL) was added 5-aminopyrazine-2-carbonitrile (0.147 g, 1.22 mmol, 1.1 eq.), Cs2CO3 (1.09 g, 3.33 mmol, 3.0 eq.), Xantphos (0.060 g, 10 mol%), followed by Pd2(dba)3 (0.050 g, 5 mol%) under nitrogen atmosphere. The resulting reaction mixture was heated at 180°C for 90 minutes in a microwave reactor. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column chromatography to obtain the title compound (0.003 g, 1%). LCMS: 354 [M+H] + ; 1H NMR(400MHz,DMSO-d6)δ11.13(br.s.,1H),10.19(br.s.,1H),8.95(s,1H),8.79-8.91(m,1H),8.38-8.50(m,1H),7.73(br.s. ,1H),7.52(s,1H),3.58(m,1H),3.51(d,J=12.28Hz,2H),2.73-2.85(m,2H),2.23(d,J=12.72Hz,2H),2.06(d,J=10.52Hz,1H).
[0405] Example 21: Synthesis of 5-(6-(4-fluorophenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.21)
[0406]
[0407] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(4-fluorophenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.3 g, 0.830 mmol, 1.0 eq.) in dioxane:water (4:1, 5.0 ml) was added sodium carbonate (0.219 g, 2.075 mmol, 2.5 eq.), 4-fluorophenylboronic acid (0.127 g, 0.913 mmol, 1.1 eq.) and Pd(dppf)Cl2DCM complex (0.033 g, 0.0415, 0.05 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 80°C for 16 hours. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography to give 245 mg of the title compound. LCMS: 421.1 [M+H] + .
[0408] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-fluorophenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(4-fluorophenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.22 g, 0.522 mmol, 1.0 eq.) in dioxane (3 mL) was added under nitrogen atmosphere. 5-aminopyrazine-2-carbonitrile (0.075 g, 0.627 mmol, 1.2 eq.), Cs2CO3 (0.340 g, 1.044 mmol, 2.0 eq.), X-phos (0.018 g, 0.0312 mmol, 0.06 eq.), followed by Pd2(dba)3 (0.014 g, 0.0156 mmol, 0.0.03 eq.) were added. The resulting reaction mixture was heated at 180 ° C for 90 minutes in a microwave reactor. TLC showed new spots formed with the starting material. Product formation was confirmed by LCMS. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography followed by flash chromatography to obtain the title compound (82 mg, 31%). LCMS: 505.2 [M+H] + .
[0409] Step-3: Synthesis of 5-(6-(4-fluorophenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-fluorophenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.060 g, 0.118 mmol) in DCM (3.0 mL) was added trifluoroacetic acid (0.2 mL) dropwise at 0°C. The resulting reaction mixture was then stirred for 40 minutes. LCMS showed the formation of the desired product. Pentane (10 mL) was added to the reaction mixture with stirring. After a suspension was formed, the organic phase was decanted. After the addition of pentane (10 mL), the remaining suspension / solid was stirred again and filtered to obtain the title compound (13 mg, 27.0%). LCMS: 405 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ8.77-8.88(m,2H),8.51(br.s.,1H),8.23(br.s.,1H),7.64(dd,J=5.70,8.33Hz,2H),7.40(t,J=8.77Hz,2H),7.31 (s,1H),3.30(d,J=12.28Hz,2H),3.10(br.s.,2H),2.84(d,J=11.84Hz,2H),1.95(br.s.,1H),1.85(d,J=14.03Hz,2H),1.27-1.39(m,2H).
[0410] Example 22: Synthesis of 5-(6-(4-phenoxyphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.22)
[0411]
[0412] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(4-phenoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.3 g, 0.828 mmol, 1.0 eq.) in dioxane:water (5:05, 5.50 ml) were added sodium carbonate (0.217 g, 2.075 mmol, 2.5 eq.), 4-phenoxyphenylboronic acid (0.212 g, 0.99 mmol, 1.2 eq.) and Pd(dppf)Cl2.DCM complex (0.027 g, 0.033 g, 0.04 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 100°C for 16 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography to obtain the title compound (200 mg, 49%). LCMS: 495.21 [M+H] + .
[0413] Step-2: Synthesis of tert-butyl 4-((6-chloro-3-(4-phenoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(4-phenoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.200 g, 0.40 mmol, 1.0 eq.) in dioxane (4 mL) was added 5-aminopyrazine-2-carbonitrile (0.063 g, 0.52 mmol, 1.3 eq.), Cs2CO3 (0.328 g, 1.0 mmol, 2.5 eq.), Xantphos (0.046 g, 0.08 mmol, 0.2 eq.) and then Pd2(dba)3 (0.036 g, 0.04 mmol, 0.1 eq.) under nitrogen atmosphere. The resulting reaction mixture was heated in a microwave reactor at 180°C for 90 min. The product formation was confirmed by LCMS. The reaction mixture was diluted with water (10 mL) and the obtained suspension was filtered through a Buchner funnel, washed with pentane. The obtained solid was redissolved in DCM and purified by flash chromatography to obtain the title compound (70 mg, 30%). LCMS: 579.2 [M+H] + .
[0414] Step-3: Synthesis of 5-(6-(4-phenoxyphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-chloro-3-(4-phenoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.070 g, 0.012 mmol) in DCM (3.0 mL) was added trifluoroacetic acid (0.2 mL) dropwise at 0°C. The resulting reaction mixture was then stirred for 2 hours. LCMS showed the formation of the desired product. Pentane (10 mL) was added to the reaction mixture with stirring. After a suspension was formed, the organic phase was decanted. After the addition of pentane (10 mL), the remaining suspension / solid was stirred again and filtered to obtain the title compound (49 mg, 84%). LCMS: 479.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.85(s,1H),8.75(br.s.,1H),7.60(d,J=8.33Hz,2H),7.47(t,J=8.11Hz,2H),7.23(t,J=7.24Hz,2H),7.07-7.19(m, 4H), 3.29 (d, J = 11.40Hz, 2H), 3.14 (d, J = 6.14Hz, 2H), 2.78-2.88 (m, 2H), 1.94 (br.s., 1H), 1.84 (d, J = 14.03Hz, 2H), 1.33 (d, J = 13.59Hz, 2H).
[0415] Example-23: Synthesis of 5-(6-(4-methoxyphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.23)
[0416]
[0417] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(4-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.300 g, 0.828 mmol, 1.0 eq.) in dioxane:water (5:05, 5.50 ml) were added sodium carbonate (0.217 g, 2.07 mmol, 2.5 eq.), 4-methoxyphenylboronic acid (0.150 g, 0.99 mmol, 1.2 eq.) and Pd(dppf)Cl2.DCM complex (0.33 g, 0.041, 0.05 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 110°C for 16 hours. TLC (50% ethyl acetate in hexane) indicated complete consumption of the starting material. The reaction mixture was diluted with water (10 ml) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography to obtain the title compound (200 mg, 56%). LCMS: 433 [M+H] + .
[0418] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(4-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.200 g, 0.46 mmol, 1.0 eq.) in DMF (3 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.067 g, 0.55 mmol, 1.2 eq.), Cs2CO3 (0.373 g, 1.15 mmol, 2.5 eq.), Xantphos (0.021 g, 0.037 mmol, 0.08 eq.) and then Pd2(dba)3 (0.016 g, 0.0181 mmol, 0.04 eq.). The resulting reaction mixture was heated in a microwave reactor at 180 °C for 90 minutes. Product formation was confirmed by LCMS. The reaction mixture was diluted with water (10 ml) and the resulting precipitate was filtered using a Buchner funnel and washed with pentane. The resulting material was redissolved in DCM and purified by flash chromatography to give the title compound (54 mg, 22%). LCMS: 517.25 [M+H] + .
[0419] Step-3: Synthesis of 5-(6-(4-methoxyphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.055 g, 0.10 mmol) in DCM (3.0 ml) was added trifluoroacetic acid (0.2 ml) dropwise at 0°C. The resulting reaction mixture was then stirred for 2 hours. LCMS showed the formation of the desired product. The reaction mixture was then concentrated under reduced pressure to obtain the crude product. The crude product was then purified using RP-HPLC to obtain the title compound (11 mg, 26%). LCMS: 417 [M+H] + ; 1H NMR(400MHz,DMSO-d6)δ8.95(br.s.,1H),8.80(s,1H),8.62(br.s.,1H),8. 37(br.s.,1H),7.46-7.56(m,J=8.33Hz,2H),7.32(s,1H),7.04-7.13(m,J= 8.77Hz,2H),6.36(br.s.,1H),3.84(s,3H),3.05(t,J=5.70Hz,2H),2.84(d ,J=11.40Hz,2H),1.91(s,3H),1.83(d,J=13.59Hz,2H),1.33-1.41(m,2H).
[0420] Example 24: Synthesis of 5-(6-(1H-indol-4-yl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.24)
[0421]
[0422] Step 1: Synthesis of tert-butyl 4-((6-chloro-3-(1H-indol-4-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.5 g, 1.38 mmol, 1.0 eq.) in dioxane:water (4:1, 10.0 ml) was added sodium carbonate (0.365 g, 3.45 mmol, 2.5 eq.), 1H-indol-4-ylboronic acid (0.397 g, 1.52 mmol, 1.1 eq.) and Pd(dppf)Cl2.DCM complex (0.056 g, 0.069, 0.05 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 80°C for 16 hours. TLC (50% ethyl acetate in hexanes) indicated complete consumption of the starting material. The reaction mixture was diluted with water (10 ml) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography followed by flash chromatography to obtain the title compound (240 mg, 39%). LCMS: 442 [M+H] + .
[0423] Step-2: Synthesis of tert-butyl 4-((6-chloro-3-(1H-indol-4-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(1H-indol-4-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.24 g, 0.543 mmol, 1.0 eq.) in DMF (3 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.078 g, 0.65 mmol, 1.2 eq.), Cs2CO3 (0.442 g, 1.35 mmol, 2.5 eq.), Xantphos (0.025 g, 0.0434 mmol, 0.08 eq.) and then Pd2(dba)3 (0.020 g, 0.0217 mmol, 0.04 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 90 minutes. TLC (50% ethyl acetate in hexane) showed that the starting material was completely consumed. Product formation was confirmed by LCMS. The reaction mixture was diluted with water (10mL) and extracted with ethyl acetate (20mL x3). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography followed by flash chromatography to obtain the title compound (32mg, 11%). LCMS: 526 [M + H] + .
[0424] Step-3: Synthesis of 5-(6-(1H-indol-4-yl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-chloro-3-(1H-indol-4-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.030 g, 0.0578 mmol) in DCM (2.0 ml) was added dropwise trifluoroacetic acid (0.2 ml) at 0°C. The resulting reaction mixture was then stirred for 30 minutes. LCMS showed the formation of the desired product. Pentane (15 mL) was added to the reaction mixture with stirring. After a suspension was formed, the reaction mixture was filtered to obtain the title compound (15 mg, 62%). LCMS: 426.3 [M+H] + ; 1H NMR(400MHz,DMSO-d6)δ11.44(br.s.,1H),8.91(br.s.,1H),8.78(br.s.,1H),8.58(br .s.,1H),8.35(br.s.,1H),7.62(d,J=8.33Hz,1H),7.46(br.s.,1H),7.24-7.34(m,1H), 7.19(d,J=7.02Hz,1H),6.30(br.s.,1H),3.28(d,J=11.84Hz,2H),3.12(br.s.,2H),2.8 3(d,J=9.21Hz,2H),1.94(br.s.,1H),1.81(d,J=13.15Hz,2H),1.32(d,J=12.72Hz,2H).
[0425] Example-25: Synthesis of 5-(6-(3-(piperidin-1-yl)phenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.25)
[0426]
[0427] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(3-(piperidin-1-yl)phenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.5 g, 1.38 mmol, 1.0 eq.) in dioxane:water (4:1, 5.0 ml) were added sodium carbonate (0.365 g, 3.45 mmol, 2.5 eq.), 3-(piperidin-1-yl)phenylboronic acid (0.312 g, 1.52 mmol, 1.1 eq.) and Pd(dppf)Cl2.DCM complex (0.056 g, 0.069, 0.05 eq.) under nitrogen purge. The reaction mixture was then stirred at 80°C for 16 hours. TLC (40% ethyl acetate in hexane) indicated complete consumption of the starting material. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography followed by flash chromatography to obtain the title compound (90 mg, 13%). LCMS: 486.2 [M+H] + .
[0428] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(3-(piperidin-1-yl)phenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(3-(piperidin-1-yl)phenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate in DMF (3 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.026 g, 0.22 mmol, 1.2 eq.), Cs2CO3 (0.150 g, 0.462 mmol, 2.5 eq.), Xantphos (0.008 g, 0.0148 mmol, 0.08 eq.) and then Pd2(dba)3 (0.07 g, 0.0074 mmol, 0.04 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 90 minutes. TLC (60% ethyl acetate in hexane) showed that the starting material was completely consumed. The product formation was confirmed by LCMS. The reaction mixture was diluted with water (10mL) and extracted with ethyl acetate (10mL x3). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography to obtain the title compound (20mg, 19%). LCMS: 570 [M + H] + .
[0429] Step-3: Synthesis of 5-(6-(3-(piperidin-1-yl)phenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile:
[0430] Trifluoroacetic acid (0.15 mL) was added dropwise to a solution of tert-butyl 4-((6-(5-cyanopyrazine-2-ylamino)-3-(3-(piperidin-1-yl)phenyl)pyridazine-4-ylamino)methyl)piperidine-1-carboxylate (0.018 g, 0.0315 mmol) in DCM (2.0 mL) at 0°C. The resulting reaction mixture was then stirred for 30 minutes. TLC (80% ethyl acetate in hexane) indicated complete consumption of the starting material. LCMS showed the formation of the desired product. Pentane (15 mL) was added to the reaction mixture under stirring. After a suspension was formed, the reaction mixture was stirred for 15 minutes and filtered to give the title compound (15 mg, 54%). LCMS: 470 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ8.90(d,J=0.88Hz,1H),8.75(s,1H),8.67(br.s.,1H),8.49(br.s.,1H),7.39-7.48(m,1H),7.28(s,4H),7.03(d,J=7.89 Hz,1H),3.08-3.21(m,6H),2.76-2.91(m,2H),1.98(br.s.,1H),1.85(d ,J=13.15Hz,2H),1.68(br.s.,4H),1.59(br.s.,3H),1.30-1.47(m,3H).
[0431] Example 26: Synthesis of 5-(6-(3-methoxyphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.26)
[0432]
[0433] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(3-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.400 g, 1.10 mmol, 1.0 eq.) in dioxane:water (6:1, 7 ml) were added sodium carbonate (0.288 g, 2.7 mmol, 2.5 eq.), 3-methoxyphenylboronic acid (0.200 g, 1.32 mmol, 1.2 eq.) and Pd(dppf)Cl2.DCM complex (0.035 g, 0.044 mmol, 0.04 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 110°C for 16 hours. TLC (50% ethyl acetate in hexane) indicated complete consumption of the starting material. The reaction mixture was diluted with water (120 ml) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography to obtain the title compound (365 mg, 77%). LCMS: 433.2 [M+H] + .
[0434] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(3-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(3-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.365 g, 0.84 mmol, 1.0 eq.) in DMF (3 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.132 g, 1.09 mmol, 1.3 eq.), Cs2CO3 (0.686 g, 2.11 mmol, 2.5 eq.), Xantphos (0.039 g, 0.067 mmol, 0.08 eq.) and then Pd2(dba)3 (0.031 g, 0.033 mmol, 0.04 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 90 minutes. TLC (50% ethyl acetate in hexane) showed complete consumption of the starting material. Product formation was confirmed by LCMS. The reaction mixture was diluted with water (10 mL) and the obtained precipitate was filtered through a Buchner funnel, washed with pentane and redissolved in DCM. The solution was concentrated in vacuo and purified by flash column chromatography to obtain the title compound (50 mg, 11%). LCMS: 517.25 [M+H] + .
[0435] Step-3: Synthesis of 5-(6-(3-methoxyphenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(3-methoxyphenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.050 g, 0.096 mmol) in DCM (3.0 ml) was added trifluoroacetic acid (0.4 ml) dropwise at 0°C. The resulting reaction mixture was then stirred for 2 hours. LCMS showed the formation of the desired product. The reaction mixture was then concentrated under reduced pressure to obtain the crude product. The crude product was then purified using RP-HPLC to obtain the title compound (6 mg, 15.0%). LCMS: 417.3 [M+H] + ; 1H NMR(400MHz, DMSO-d6)δ9.01(br.s.,1H),8.78(d,J=1.32Hz,1H),7.45(t,J=8.11Hz,1H),7.29(s,1H),7.00-7.16(m,4H),6.35(br.s.,1H),3.82 (s, 3H), 3.11 (d, J = 11.84Hz, 2H), 3.03 (d, J = 5.70Hz, 2H), 2.64 (d, J = 19.73Hz, 2H), 1.84 (br.s., 1H), 1.72 (d, J = 12.72Hz, 2H), 1.13-1.26 (m, 2H).
[0436] Example-27: Synthesis of 5-(6-(4-(hydroxymethyl)phenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.27)
[0437]
[0438] Step-1: Synthesis of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate:
[0439] To a solution of 3,4,6-trichloropyridazine (1.0 g, 5.45 mmol) in acetonitrile (20.0 ml) was added DIPEA (2.37 ml, 13.62 mmol) at room temperature, followed by tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (1.22 g, 5.72 mmol). The resulting reaction mixture was stirred at room temperature for 2 hours. TLC (50% ethyl acetate in hexane) showed that the raw material was completely consumed. The reaction mixture was then concentrated, diluted with DM water (20 ml) and extracted with ethyl acetate (30 ml x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography to obtain the title compound (850 mg, 43%). LCMS: 380.4 [M + H] + .
[0440] Step-2: Synthesis of tert-butyl 4-((6-chloro-3-(4-(hydroxymethyl)phenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.400 g, 1.10 mmol, 1.0 eq.) in dioxane:water (5:05, 5.5 ml) were added sodium carbonate (0.290 g, 2.76 mmol, 2.5 eq.), 4-(hydroxymethyl)phenylboronic acid (0.200 g, 1.32 mmol, 1.2 eq.) and Pd(dppf)Cl2.DCM complex (0.036 g, 0.044 mmol, 0.04 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 110°C for 16 hours. TLC (50% ethyl acetate in hexane) indicated complete consumption of the starting material. The reaction mixture was diluted with water (50 ml) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography to give the title compound (195 mg, 40.08%). LCMS: 433.2 [M+H] + .
[0441] Step-3: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-(hydroxymethyl)phenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: Under nitrogen atmosphere, tert-butyl 4-((6-chloro-3-(4-(hydroxymethyl)phenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.193 g, 0.446 mmol, 1.0 eq.) was added to a solution of DMF (3 mL) ) solution was added with 5-aminopyrazine-2-carbonitrile (0.070 g, 0.58 mmol, 1.3 eq.), Cs2CO3 (0.362 g, 1.11 mmol, 2.5 eq.), Xantphos (0.020 g, 0.037 mmol, 0.08 eq.), followed by Pd2(dba)3 (0.016 g, 0.017 mmol, 0.04 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 90 minutes. TLC (50% ethyl acetate in hexane) showed complete consumption of the starting material. Product formation was confirmed by LCMS. The reaction mixture was diluted with water (10 mL) and the resulting precipitate was filtered with a Buchner funnel and washed with pentane. The resulting material was redissolved in DCM and purified by flash chromatography to obtain the title compound (57 mg, 13%). LCMS: 517 [M+H] + .
[0442] Step-4: Synthesis of 5-(6-(4-(hydroxymethyl)phenyl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(4-(hydroxymethyl)phenyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.048 g, 0.083 mmol) in DCM (3.0 ml) was added trifluoroacetic acid (0.4 ml) dropwise at 0°C. The resulting reaction mixture was then stirred for 2 hours. LCMS showed the formation of the desired product. The reaction mixture was then concentrated under reduced pressure to obtain the crude product. The crude product was then purified using RF-HPLC to obtain the title compound (13.6 mg, 34%). LCMS: 417.3 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ8.87(br.s.,1H),8.80(br.s.,1H),8.58(br.s.,1H),8.33(br.s.,1H),7.51(s,1H),7.55(s,2H),7.30(br.s.,1H),4.6 1(br.s.,2H),3.29(br.s.,2H),3.13(br.s.,2H),2.84(d,J=11.84Hz,2H),1.96(br.s.,1H),1.84(d,J=12.28Hz,2H),1.35(d,J=10.96Hz,2H).
[0443] Example 28: Synthesis of 5-(6-(1-methyl-1H-pyrazol-3-yl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.28):
[0444]
[0445] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.600 g, 1.65 mmol, 1.0 eq.) in dioxane:water (5:05, 5.5 ml) were added sodium carbonate (0.382.87 g, 3.64 mmol, 2.2 eq.), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.441.7 g, 2.15 mmol, 1.3 eq.) and Dikis (0.0446 g, 0.066, 0.04 eq.) under nitrogen purge. The reaction mixture was then purged for another 5 minutes and stirred at 110°C for 16 hours. TLC (50% ethyl acetate in hexane) indicated complete consumption of the starting material. The reaction mixture was diluted with water (50 ml) and extracted with ethyl acetate (50 mL x2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography to obtain the title compound (280 mg, 52%). LCMS: 407.2 [M+H] + .
[0446] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To tert-butyl 4-((6-chloro-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.280 g, 0.68 mmol, 1.0 eq.) in DMF was added under nitrogen atmosphere. 5-aminopyrazine-2-carbonitrile (0.108 g, 0.89 mmol, 1.3 eq.), Cs2CO3 (0.562 g, 1.72 mmol, 2.5 eq.), Xantphos (0.0318 g, 0.055 mmol, 0.08 eq.) were added to the (3 mL) solution, followed by Pd2(dba)3 (0.025 g, 0.027 mmol, 0.04 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 90 minutes. TLC (50% ethyl acetate in hexane) showed complete consumption of the starting material. Product formation was confirmed by LCMS. The reaction mixture was diluted with water (10 ml) and the resulting precipitate was filtered through a Buchner funnel and washed with pentane. The resulting material was redissolved in DCM and purified by flash chromatography to give the title compound (40 mg, 11%). LCMS: 491.2 [M+H] + .
[0447] Step-3: Synthesis of 5-(6-(1-methyl-1H-pyrazol-3-yl)-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(1-methyl-1H-pyrazol-3-yl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.030 g, 0.061 mmol) in DCM (3.0 ml) was added trifluoroacetic acid (0.4 ml) at 0°C. The resulting reaction mixture was then stirred for 2 hours. LCMS showed the formation of the desired product. Pentane (15 mL) was added to the reaction mixture with stirring. After a suspension was formed, the reaction mixture was filtered to obtain the title compound (11 mg, 46%). LCMS: 391.21 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ8.88(br.s.,1H),8.82(s,1H),8.77(br.s.,1H),8.52(br.s.,1H),8.21(br.s.,1H),7.92(br.s.,1H),7.38(s,1H),6 .98(br.s.,1H),3.99(s,3H),3.24-3.38(m,2H),2.90(d,J=9.65Hz,4H),1.99(br.s.,1H),1.91(d,J=12.72Hz,2H),1.44(d,J=14.91Hz,2H).
[0448] Example-29: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxamide (Compound No. 1.29)
[0449]
[0450] Step-1: Synthesis of methyl 6-chloro-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxylate: To a solution of methyl 4,6-dichloropyridazine-3-carboxylate (0.5 g, 0.0024 mol, 1.0 eq.) and (1-methylpiperidin-4-yl)methanamine (0.275 g, 0.0024 mol, 1.0 eq.) in ACN (10 mL) was added DIPEA (0.8 mL, 0.0048 mmol, 2.0 eq.). The reaction mixture was stirred for 16 hours. After completion, the reaction mixture was concentrated in vacuo to obtain a crude product, which was purified by normal phase silica gel column chromatography to obtain the title compound (1.0 g, 73%). LCMS: 286 [M+H] + .
[0451] Step-2: Synthesis of 6-chloro-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxamide: To a solution of methyl 6-chloro-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxylate (0.5 g, 0.0017 mol, 1.0 eq.) was added methanolic ammonia at room temperature. The reaction mixture was stirred for 30 minutes. After completion, the reaction mixture was concentrated in vacuo to obtain the title compound (0.4 g, 84%). LCMS: 271 [M+H] + .
[0452] Step-3: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxamide: To a solution of methyl 6-chloro-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxylate (0.2 g, 0.7 mmol, 1.0 eq.) in DMF (4 mL) under nitrogen atmosphere, 5-aminopyrazine-2-carbonitrile (0.106 g, 0.8 mmol, 1.2 eq.), Cs2CO3 (0.72 g, 2.2 mmol, 3.0 eq.), Xantphos (0.042 g, 10 mol%), and then Pd2(dba)3 (0.033 g, 5 mol%) were added. The resulting reaction mixture was heated at 180°C for 90 minutes using a microwave reactor. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by RP-HPLC to give the title compound (0.026 g, 10%). LCMS: 355 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ11.00(br.s.,1H),8.89-9.04(m,2H),8.75-8.84(m,1H),8.37(br.s.,1H),7.64(br.s.,1H),7.40(s,1H),3.8 7(dd,J=3.07,10.96Hz,2H),3.23-3.30(m,2H),3.11(t,J=6.14Hz,2H),1.87(br.s.,1H),1.62(d,J=11.84Hz,2H),1.21-1.37(m,2H).
[0453] Example-30: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxamide (Compound No. 1.30)
[0454]
[0455] Step-1: Synthesis of 6-chloro-N-methyl-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxamide: To a solution of methyl 6-chloro-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxylate (0.500 g, 1.7 mmol, 1.0 eq.) in methanol were added K2CO3 (0.726 g, 5.2 mmol, 3.0 eq.) and methylamine hydrochloride (0.236 g, 3.5 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated in vacuo and diluted with water and extracted with DCM (75 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the title compound (0.230 g, 47%). LCMS: 285 [M+H] + .
[0456] Step-2: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxamide: To a solution of 6-chloro-N-methyl-4-((tetrahydro-2H-pyran-4-yl)methylamino)pyridazine-3-carboxamide (0.230 g, 0.8 mmol, 1.0 eq.) in DMF (4 mL) was added 5-aminopyrazine-2-carbonitrile (0.116 g, 0.9 mmol, 1.2 eq.), Cs2CO3 (0.79 g, 2.4 mmol, 3.0 eq.), Xantphos (0.046 g, 10 mol%), followed by Pd2(dba)3 (0.037 g, 5 mol%) under nitrogen atmosphere. The resulting reaction mixture was heated at 180°C for 90 minutes using a microwave reactor. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by RP-HPLC to give the title compound (0.056 g, 19%). LCMS: 369 [M+H] + ;1H NMR (400MHz, DMSO-d6) δ8.87-9.07(m,3H),8.79(s,1H),7.39(s,1H),3.87(d,J=7.89Hz,2H),3.29(t,J=10.96Hz,2H),3.10(t, J=5.92Hz,2H),2.79(d,J=4.82Hz,3H),1.88(br.s.,1H),1.75(s,1H),1.62(d,J=11.84Hz,2H),1.29(dt,J=8.33,12.06Hz,2H).
[0457] Example-31: Synthesis of 5-(6-isopropoxy-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.31)
[0458]
[0459] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-isopropoxypyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.4 g, 1.1 mmol, 1.0 eq.) in ACN (10 mL) was added isopropanol (0.2 mL) and K2CO3 (0.3 g, 2.2 mmol, 2.0 eq.) at room temperature. The reaction mixture was stirred with heating at 80°C for 18 hours. After completion, the reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column chromatography to obtain the title compound (0.18 g, 42%). LCMS: 385 [M+H] + .
[0460] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-isopropoxypyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-isopropoxypyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.18 g, 0.4 mmol, 1.0 eq.) in DMF (4 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.068 g, 0.5 mmol, 1.2 eq.), Cs2CO3 (0.45 g, 1.3 mmol, 3.0 eq.), Xantphos (0.027 g, 10 mol%) followed by Pd2(dba)3 (0.020 g, 5 mol%). The resulting reaction mixture was heated in a microwave reactor at 180°C for 1 hour. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by RP-HPLC to give the title compound (0.050 g, 57%). LCMS: 469 [M+H] + .
[0461] Step-3: Synthesis of 5-(6-isopropoxy-5-(piperidin-4-ylmethylamino)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-isopropoxypyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.05 g, 0.1 mmol, 1.0 eq.) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 30 minutes. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added, and the resulting precipitate was filtered and washed with diethyl ether to obtain the title compound as a TFA salt (5 mg, 14%). LCMS: 369 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ9.08(br.s.,1H),8.70(s,1H),6.83(s,1H),6.49(br.s.,1H),5.26-5.3 7(m,1H),2.85-3.04(m,4H),1.73(br.s.,5H),1.59(d,J=13.59Hz,2H),1.35(d,J=6.14Hz,6H).
[0462] Example-32: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N,N-dimethyl-4-(piperidin-4-ylmethylamino)pyridazine-3-carboxamide (Compound No. 1.32)
[0463]
[0464] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(dimethylcarbamoyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of methyl 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methylamino)-6-chloropyridazine-3-carboxylate (0.6 g, 1.56 mmol, 1.0 eq.) in methanol (50 mL) was added potassium carbonate (0.645 g, 4.68 mmol, 3.0 eq.) followed by dimethylamine hydrochloride (0.636 g, 7.80 mmol, 5.0 eq.). The resulting reaction mixture was stirred at room temperature for 6 hours. TLC (60% ethyl acetate in hexane) indicated complete consumption of the starting material. The reaction mixture was concentrated. The reaction mixture was diluted with water (20 ml) and extracted with ethyl acetate (40 ml x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash chromatography to give (320 mg, 51.6%). LCMS: 398.1 [M+H] + .
[0465] Step-2: Synthesis of 6-(5-cyanopyrazin-2-ylamino)-N,N-dimethyl-4-(piperidin-4-ylmethylamino)pyridazine-3-carboxamide: To a solution of tert-butyl 4-((6-chloro-3-(dimethylcarbamoyl)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.300 g, 0.755 mmol, 1.0 eq.) in DMF (4.0 mL) under nitrogen atmosphere were added 5-aminopyrazine-2-carbonitrile (0.108 g, 0.906 mmol, 1.2 eq.), Cs2CO3 (0.614 g, 1.88 mmol, 2.5 eq.), Xantphos (0.034 g, 0.060 mmol, 0.08 eq.) and then Pd2(dba)3 (0.027 g, 0.0302 mmol, 0.04 eq.). The resulting reaction mixture was heated at 180 ° C in a microwave reactor for 90 minutes. TLC (ethyl acetate) showed that the raw material was completely consumed. The reaction mixture was diluted with water (15ml) and the resulting precipitate was filtered through a Buchner funnel. The filtrate was then concentrated to remove DMF. The resulting reaction mixture was diluted with DM water (10mL) and washed with ethyl acetate (10mL). The water layer was then concentrated to obtain 300mg of crude product, which was then purified using RF-HPLC to obtain 10mg of the title compound. LCMS: 382[M+H] + ;1H NMR (400MHz, METHANOL-d4) δ8.73(br.s.,2H),7.27(br.s.,1H),3.73(td,J=6.58,13.15Hz,2H),3.45(d,J=11 .84Hz, 2H), 3.23 (d, J = 7.02Hz, 2H), 3.15 (d, J = 15.79Hz, 6H), 3.01 (t, J = 12.50Hz, 2H), 2.05 (d, J = 12.28Hz, 3H).
[0466] Example-33: Synthesis of 5-(5-(piperidin-4-ylmethylamino)-6-(2,2,2-trifluoroethoxy)pyridazin-3-ylamino)pyrazine-2-carbonitrile (Compound No. 1.33)
[0467]
[0468] Step-1: Synthesis of tert-butyl 4-((6-chloro-3-(2,2,2-trifluoroethoxy)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((3,6-dichloropyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.4 g, 1.1 mmol, 1.0 eq.) in ACN (5 mL) was added 2,2,2-trifluoroethanol (0.13 g, 1.3 mmol, 1.2 eq.) and LiOH.H2O (0.09 g, 2.2 mmol, 2.0 eq.) at room temperature. The reaction mixture was stirred with heating at 80°C for 18 hours. After completion, the reaction mixture was diluted with water and extracted with ethyl acetate (75 mL x 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by normal phase chromatography to obtain the title compound (0.35 g, 75%). LCMS: 425 [M+H] + .
[0469] Step-2: Synthesis of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(2,2,2-trifluoroethoxy)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate: To a solution of tert-butyl 4-((6-chloro-3-(2,2,2-trifluoroethoxy)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.35 g, 0.8 mmol, 1.0 eq.) in DMF (5 mL) was added 5-aminopyrazine-2-carbonitrile (0.12 g, 0.99 mmol, 1.2 eq.), Cs2CO3 (0.80 g, 2.4 mmol, 3.0 eq.), Xantphos (0.047 g, 10 mol%), followed by Pd2(dba)3 (0.037 g, 5 mol%) under nitrogen atmosphere. The resulting reaction mixture was heated in a microwave reactor at 180°C for 1 hour. The product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by RP-HPLC to give the title compound (0.030 g, 7%). LCMS: 509 [M+H] + .
[0470] Step-3: Synthesis of 5-(5-(piperidin-4-ylmethylamino)-6-(2,2,2-trifluoroethoxy)pyridazin-3-ylamino)pyrazine-2-carbonitrile: To a solution of tert-butyl 4-((6-(5-cyanopyrazin-2-ylamino)-3-(2,2,2-trifluoroethoxy)pyridazin-4-ylamino)methyl)piperidine-1-carboxylate (0.03 g, 0.06 mmol, 1.0 eq.) in DCM (5 mL) was added TFA (0.5 mL) and the resulting reaction mixture was stirred at room temperature for 60 min. The progress of the reaction was monitored by LCMS. Diethyl ether (10 mL) was added and the resulting precipitate was filtered and washed with diethyl ether to obtain a crude compound, which was purified by RP-HPLC to obtain the title compound (2 mg, 8%). LCMS: 409 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ10.64(br.s.,1H),9.00(br.s.,1H),8.77(br.s.,1H),8.52(br.s.,1H),7.12(br.s.,1H),6.89(br.s.,1H),5.01-5 .20(m,2H),3.09(br.s.,2H),2.82(t,J=11.40Hz,2H),1.91(br.s.,1H),1.81(d,J=11.40Hz,2H),1.37(d,J=11.84Hz,2H),1.23(br.s.,2H).
[0471] Example-34: Separation of a racemic mixture of 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide (Compound No. 1.34) and (Compound No. 1.35)
[0472]
[0473] The racemic compound 6-(5-cyanopyrazin-2-ylamino)-N-methyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide (25 mg) was chirally purified by SFC to give two isomers at Rt = 9.10 and 10.12, respectively, using the following method.
[0474] Method: Eluent A: liquid carbon dioxide (food grade), eluent B: 0.2% DEA in methanol; isocratic elution composition: liquid carbon dioxide (60%): co-solvent percentage: 40%, (run time: 20 minutes); flow rate 56g / min, column box temperature: 400℃; PDA scan: 210-400nm. Instrument: Waters Method Station Column: Chiralcel-OXH (250x21) mm: 5μm; LCMS: 370 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ11.11(br.s.,1H),8.97-9.08(m,2H),8.86-8.95(m,2 H),8.81(s,1H),7.50(s,1H),4.05(d,J=9.65Hz,1H),3.91(br.s.,1H),3.68- 3.76(m,2H),3.43(d,J=13.59Hz,2H),3.33(d,J=11.84Hz,2H),3.22(d,J=11. 84Hz, 1H), 3.03 (br.s., 1H), 2.89 (d, J = 11.40Hz, 1H), 2.80 (d, J = 4.82Hz, 2H).
[0475] Example-35: Synthesis of 6-(6-cyanopyridin-3-ylamino)-N-methyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide (Compound No. 1.36)
[0476]
[0477] Step-1: Synthesis of tert-butyl 2-((6-(6-cyanopyridin-3-ylamino)-3-(methylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate: To a solution of tert-butyl 2-((6-chloro-3-(methylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.100 g, 0.25 mmol, 1.0 eq.) in dioxane (4 mL) under nitrogen atmosphere were added 5-aminopyridine-2-carbonitrile (0.037 g, 0.31 mmol, 1.2 eq.), Cs2CO3 (0.25 g, 0.77 mmol, 3.0 eq.), Xantphos (0.015 g, 0.025 mmol, 0.1 eq.) followed by the addition of Pd2(dba)3 (0.011 g, 0.012 mmol, 0.05 eq.). The resulting reaction mixture was heated in a microwave reactor at 180 ° C for 1 hour. Product formation was confirmed by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (50mL x3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by RP-HPLC to obtain the title compound (0.020 g, 17%). LCMS: 469 [M+H] + .
[0478] Step-2: Synthesis of 6-(6-cyanopyridin-3-ylamino)-N-methyl-4-(morpholin-2-ylmethylamino)pyridazine-3-carboxamide: To a solution of tert-butyl 2-((6-(6-cyanopyridin-3-ylamino)-3-(methylcarbamoyl)pyridazin-4-ylamino)methyl)morpholine-4-carboxylate (0.020 g, 0.04 mmol) in DCM (2 mL) was added TFA (0.20 mL) at room temperature and the resulting reaction mixture was stirred at room temperature for 1 hour. The formation of the product was confirmed by LCMS and TLC. Diethyl ether was added to the reaction mixture to obtain a precipitate, which was vacuum filtered to obtain the title compound (0.005 g, 36%). LCMS: 369 [M+H] + ; 1HNMR(400MHz,DMSO-d6)δ10.06(br.s.,1H),9.07(br.s.,1H),8.94(br.s.,2H),8.88(br .s.,1H),8.42(d,J=7.89Hz,1H),7.94(d,J=8.33Hz,1H),6.38(br.s.,1H),4.04(d,J=12 .72Hz,1H),3.89(br.s.,1H),3.69-3.76(m,3H),3.30(d,J=8.33Hz,1H),3.22(d,J=12.7 2Hz, 1H), 3.02 (br.s., 1H), 2.87 (d, J = 10.09Hz, 1H), 2.79 (d, J = 3.51Hz, 2H), 2.07 (s, 1H).
[0479] Biological Examples
[0480] Example-B1: CHK-1 kinase assay
[0481] Based on Z-LYTE TM TR-FRET assay to determine the IC of compounds inhibiting CHK-1 kinase 50 Value or percentage inhibition at a specified concentration. Kinase reactions were performed in a 10 μL volume in a small volume 384-well plate. The concentration of substrate (SerThr 19) was kept at 2 μM in the assay, and the kinase reaction buffer consisted of 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 m MDTT. Compounds serially diluted (3-fold) in DMSO (0.5% in the final reaction) were incubated with a mixture of CHK-1 kinase (5 ng / ml; Cat# P3040, ThermoFisher), Ser Thr 19 (2 μM; Cat# PV4529, ThermoFisher), ATP (53 μM; Cat# PV3227, ThermoFisher) and buffer. The kinase reaction was performed at room temperature for 1 hour, after which 5 μL of 1:256 diluted Development Reagent A was added. The plates were incubated at room temperature for 60 min before use for Z-LYTE TM Z-LYTE for TR-FRET TM The filter blocks were read on a BMG Pherastar plate reader.
[0482] The resulting TR-FRET emission ratio was used to calculate the percent inhibition by normalizing with the control using the following formula:
[0483] [% inhibition = 1 - {(% phosphorylation样品 / % Phosphorylation 对照品(0%抑制)}*100].
[0484] To calculate IC 50 The obtained percentage inhibition was plotted against the concentration of the inhibitor and the data were fitted to a sigmoidal dose-response curve with a variable slope. The IC 50 .
[0485] The results of percent inhibition of CHK-1 at 1 μM and 5 μM are shown in Table-B1.
[0486] Table-B1: Percentage inhibition of CHK-1 at 1 μM and 5 μM
[0487]
[0488]
[0489] *ND = Not Determined
[0490] ICs against CHK-1 50 The results are shown in Table-B2.
[0491] Table-B2: IC against CHK-1 50
[0492] Compound No. <![CDATA[CHK-1 IC 50 (μM)]]> 1.2 0.070 1.3 0.092 1.5 >10 1.7 2.01 1.8 5.81 1.9 >10
[0493] *ND = Not Determined
[0494] Example-B2: CHK-2 Kinase Assay
[0495] Based on Z-LYTE TM TR-FRET Assay to Determine the IC of Compounds Inhibiting CHK-2 Kinase 50Values or percent inhibition at a specified concentration. Kinase reactions were performed in a 10 μL volume in a small volume 384-well plate. The concentration of substrate (SerThr 07) was kept at 1 μM in the assay and the kinase reaction buffer consisted of 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. Compounds serially diluted (3-fold) in DMSO (0.5% in the final reaction) were incubated with a mixture of CHK-2 kinase (5 ng / ml; Cat#PV3367, ThermoFisher), Ser Thr 07 (1 μM; Cat#PV3208, ThermoFisher), ATP (84 μM; Cat#PV3227, ThermoFisher) and buffer. The kinase reaction was performed at room temperature for 1 hour, after which 5 μL of a 1:45000 dilution of Development Reagent A was added. The plates were incubated at room temperature for 60 minutes before use for Z-LYTE TM Z-LYTE for TR-FRET TM The filter blocks were read on a BMG Pherastar plate reader.
[0496] The resulting TR-FRET emission ratio was used to calculate the percent inhibition by normalizing with the control using the following formula:
[0497] [% inhibition = 1 - {(% phosphorylation 样品 / % Phosphorylation 对照品(0%抑制)}*100].
[0498] To calculate IC 50 The obtained percentage inhibition was plotted against the concentration of the inhibitor and the data were fitted to a sigmoidal dose-response curve with a variable slope. The IC 50 .
[0499] The results of percent inhibition of CHK-2 at 0.1 μM and 1 μM are shown in Table-B3.
[0500] Table-B3: Percentage inhibition of CHK-2 at 0.1 μM and 1 μM
[0501]
[0502] Example-B3: Cell viability assay:
[0503] Protocol for cell viability assay of CHK-1 inhibitors in different cell lines:
[0504] Cell lines such as colon cancer cell HT29 (( HTB-38 TM ); lung epithelial cancer cell A549( CCL-185 TM ); pancreatic cancer cell line MIA PaCa-2 ( CRL-1420 TM )、Panc-1(CRL-1469 TM ) and AsPC-1(( CRL-1682 TM ); Colorectal cancer cell HCT-116( CCL-247 TM ); peripheral blood cells MDAMB-231( HTB-26 TM )、TNBC、THP-1( TIB-202 TM ) and MV-4-11( CRL-9591 TM) were plated in the respective culture medium containing 10% FBS (Cat#16000044; Gibco) [as recommended by ATCC]. The cells were grown in a Nuaire incubator (humidified) in 5% CO2 at 37°C (culture conditions) for 24 hours (adherent cells). After 24 hours (adherent cells), serially diluted compounds (100 μl) were added to the culture plates (in the case of suspension cells, immediately after plating) and the cultures were further incubated under culture conditions for 72-144 hours depending on the cell type. The experiments were terminated at the completion of the respective incubation with drugs by replacing the culture medium with 100 μl of 1 mM resazurin (R7017; Sigma) prepared in the culture medium and the plates were further incubated under culture conditions for 4 hours. In the case of incubation with drugs for 144 hours, the drugs were replenished once with fresh culture medium after 72 hours. Fluorescence was then measured using a multimode plate reader (Biotek Synergy Neo) at an excitation wavelength of 535 nm and an emission wavelength of 590 nm to obtain relative fluorescence units. Data analysis was performed by subtracting the background fluorescence (medium blank only) value from each reading and then normalized to vehicle control (DMSO-treated cells) to obtain percent survival / proliferation. The percentage survival at different doses was used to calculate IC by fitting the curves to a "four-parameter variable slope logistic model" using Prism Graph Pad. 50 The results of the cell viability assay are provided in Table-B4.
[0505] Table-B4
[0506]
[0507] *ND = Not Determined
[0508] It should be understood that the above examples and embodiments are for illustrative purposes only, and that those skilled in the art are advised to adopt various modifications or changes thereof, and that such modifications or changes will be included within the spirit and scope of the present application and the scope of the appended claims.
Claims
1. A compound of formula (IA) or a salt thereof: in, Y is CR y ; A is The wavy lines indicate the points of connection to the rest of the molecule; R y is hydrogen; D is -(C1-C6 alkylene)NR 11 R 12 , 3- to 6-membered heterocyclic group, -(C1-C6 alkylene)C3-C6 cycloalkyl group or -(C1-C6 alkylene)3- to 6-membered heterocyclic group, each of which is optionally replaced by R 2 Substituted; the heterocyclic group is a saturated or unsaturated non-aromatic group containing 1 to 4 heteroatoms selected from nitrogen, sulfur or oxygen; L is -O- or -NH-; R 1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, C6 aryl, 5- to 10-membered heteroaryl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 haloalkyl, -OR 13 、-SR 13 、-S(O)2R 13 、-S(O)2NR 14 R 15 、-NR 13 S(O)2R 14 、-NR 14 R 15 、-C(O)R 13 、-C(O)OR 13 or -C(O)NR 14 R 15 ; where each R 1 Optionally R 3 Substituted; the heterocyclic group is a saturated or unsaturated non-aromatic group containing 1 to 4 heteroatoms selected from nitrogen, sulfur or oxygen; R 2 For-OR 16 、-NR 17 R 18 、-C(O)R 16 、-NR 16 C(O)R 17 、-C(O)OR 16 , or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2; R 3 is C2-C6 alkenyl, -CN, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, -OR 16 、-NR 17 R 18 、-C(O)R 16 、-NR 16 C(O)R 17 、-C(O)OR 16 , C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2; the heterocyclyl is a saturated or unsaturated non-aromatic group containing 1 to 4 heteroatoms selected from nitrogen, sulfur or oxygen; Each R 11 and R 12 are independently hydrogen or C1-C6 alkyl; each R 13 , R 14 and R 15 are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, or -(C1-C3 alkylene)5- to 6-membered heteroaryl, wherein R 13 , R 14 and R 15 Each of which is independently optionally substituted with halogen; Each R 16 , R 17 and R 18 are independently hydrogen, C2-C6 alkenyl or C1-C6 alkyl optionally substituted by oxo, -OH, halogen or -NH2.
2. The compound according to claim 1, wherein D is -(C1-C6 alkylene)NR 11 R 12 , 3- to 6-membered heterocyclic group, -(C1-C6 alkylene)C3-C6 cycloalkyl group or -(C1-C6 alkylene)3- to 6-membered heterocyclic group, each of which is optionally replaced by R 2 Substitution; wherein R 2 For-NR 17 R 18 、-NR 16 C(O)R 17 or a C1-C6 alkyl group optionally substituted by oxo, -OH, halogen or -NH2; the heterocyclic group is a saturated or unsaturated non-aromatic group containing 1 to 4 heteroatoms selected from nitrogen, sulfur or oxygen.
3. The compound according to claim 1, wherein D is selected from in, The wavy line indicates the point of attachment to the rest of the molecule.
4. The compound according to claim 3, wherein D is 5. A compound according to any one of claims 1 to 4, wherein R 1 -C(O)NR 14 R 15 , where R 14 and R 15 Independently selected from hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl.
6. A compound according to any one of claims 1 to 4, wherein R 1 Selected from hydrogen, -CH3, in, The wavy line indicates the point of attachment to the rest of the molecule.
7. The compound according to claim 6, wherein R 1 Selected from hydrogen, -CH3, 8. The compound according to claim 7, wherein R 1 Selected from 9. The compound according to claim 1, wherein the compound is the following compound or a salt thereof: Among them, D, L, R 1 and R y As defined in claim 1.
10. The compound according to claim 1, wherein the compound is a compound of formula (IVa-8) or a salt thereof: Among them, D, L, R y and R 15 As defined in claim 1.
11. The compound according to claim 1, wherein the compound is a compound of formula (IVa-13) or a salt thereof, Among them, D and R 15 and R y As defined in claim 1.
12. The compound according to claim 1, wherein the compound is selected from:
13. Use of a compound according to any one of claims 1 to 12 for the manufacture of a medicament for treating a disease or condition mediated by a checkpoint kinase (CHK) in a subject in need thereof.
14. Use of a compound according to any one of claims 1 to 12 for the manufacture of a medicament for treating a disease or condition mediated by CHK-1 in a subject in need thereof.
15. A pharmaceutical composition comprising the compound or salt thereof according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier.
16. Use of a compound according to any one of claims 1 to 12 in the manufacture of a medicament for treating cancer in a subject in need thereof.
17. A kit comprising the compound or a salt thereof according to any one of claims 1 to 12.
